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1. Abstract 
Telomeres at ends of eukaryotic chromosomes contain accessory proteins and 
telomeric DNA, which is composed of tandem repeats of a G-rich motif 
(5’-TTAGGG-3’ in humans) with 3’ overhang termed G-tail. In normal somatic cells, 
telomeric DNA shortens with every cell division due to an end replication problem. The 
shortening of telomeric DNA finally leads to apoptosis. In contrast, in most of tumor 
cells (85-90%), highly-activated telomerase maintains the length of telomeric DNA, 
which is a critical biological event for carcinogenesis. The specificity and universality 
of the telomerase activity for tumor cells implies two important suggestions: (i) 
inhibition of the telomerase activity should allow an anticancer therapy with few 
side-effects and (ii) detection of the telomerase activity should allow a precise cancer 
diagnosis. Thus, the author attempted to achieve two purposes: (i) elucidation of rules to 
design anticancer drugs with efficient telomerase inhibitory effect, and (ii) development 
of an assay for telomerase activity without false results.  
1.1. Elucidation of Rules to Design Anticancer Drugs with Efficient Telomerase 
Inhibitory Effect (Main Papers 1 and 2) 
Since it was found that G-quadruplex structure formed by telomeric DNA inhibits 
telomerase activity, many G-quadruplex-ligands have been screened or developed 
toward development of anticancer drugs. Most of them contain a large π planar core 
with peripheral cationic groups in order to bind to G-quadruplex via π-π stacking and 
electrostatic attractive interactions. However, cationic G-quadruplex-ligands did not 
often show the desired anticancer effects in cellular assays despite of their highly 
efficient telomerase inhibition in vitro. This divergence is at least partly due to 
differences between chemical conditions in vitro and in vivo. Based on previous studies 
on the conventional G-quadruplex-ligands, it was expected that excess double-stranded 
DNA (dsDNA) found in genome DNA and molecular crowding (MC) in cell nuclei may 
reduce their capacities to bind to G-quadruplex and to inhibit telomerase activity. 
Therefore, in order to acquire a strategy to design G-quadruplex-ligands that exert the 
desired functions even in cell nuclei, the author systematically examined various 
cationic and anionic G-quadruplex-ligands under cell nuclei-mimicking conditions, in 
which excess dsDNA and MC cosolutes exist. 
The capacities of an anionic copper phthalocyanine with four sodium salt forms of 
sulfo groups, copper (II) phthalocyanine 3,4’,4’’,4’’’-tetrasulfonic acid, tetrasodium salt 
(Cu-APC), to bind to a human telomeric oligo G-quadruplex and to inhibit telomerase 
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activity were investigated. Based on visible absorbance titration experiments, Cu-APC 
bound to the G-quadruplex with a Kd value of 42 µM in the presence of 100 mM KCl at 
25°C, and little or no absorbance change was observed for single-stranded DNA 
(ssDNA) or dsDNA. These results indicate that Cu-APC can bind to the G-quadruplex 
with high selectivity over ssDNA and dsDNA. Notably, the Kd value of Cu-APC for the 
G-quadruplex in the presence of excess decoy dsDNA, λ DNA, was almost the same as 
that in the absence of λ DNA. This high selectivity is attributed to that an electrostatic 
repulsion between anionic groups of Cu-APC and phosphate groups of dsDNA prevents 
Cu-APC from binding to dsDNA, although interaction between Cu-APC and the 
G-quadruplex is kept via π-π stacking interaction. Results obtained with a modified 
telomeric repeat amplification protocol (TRAP) assay were in accordance with results 
from the binding studies; Cu-APC inhibited telomerase activity with an IC50 value of 
1.2 µM in both the absence and presence of λ DNA. In addition, the telomerase 
inhibitory effect of metal-free and nickel anionic phthalocyanines was not significantly 
affected by λ DNA. These results indicate that the coordination metal has very little 
effect on anionic phthalocyanine-mediated telomerase inhibition. In contrast, 
5,10,15,20-tetra(N-methyl-4-pyridyl)porphyrin (TMPyP4), which is a cationic 
porphyrin, bound to not only the G-quadruplexdid but also ssDNA and dsDNA. In 
accordance with these results, TMPyP4 lost its telomerase inhibitory effect in the 
presence of λ DNA, although it inhibited telomerase activity in the absence of λ DNA. 
The loss of the telomerase inhibitory effect of TMPyP4 should be due to non-specific 
binding between cationic groups of TMPyP4 and phosphate groups of λ DNA. Based on 
these findings, it is possible to conclude that, even in the presence of excess genomic 
dsDNA in cell nuclei, anionic phthalocyanines could efficiently inhibit telomerase 
activity. 
Next, the telomeric G-quadruplex-binding and telomerase-inhibiting capacities of two 
cationic (TMPyP4 and N,N'-bis[2-(1-piperidino)ethyl]-3,4,9,10-perylenetetracarboxylic 
diimide (PIPER)) and two anionic (Cu-APC and Fe(III)-protoporphyrin IX (Hemin)) 
G-quadruplex-ligands were examined under MC conditions. Osmotic experiments 
showed that binding of the anionic ligands, which bind to G-quadruplex DNA via π-π 
stacking interactions, caused some water molecules to be released from the 
G-quadruplex/ligand complex; in contrast, a substantial number of water molecules 
were taken up upon electrostatic binding of the cationic ligands to G-quadruplex DNA. 
These behaviors of water molecules maintained and reduced the binding affinities of the 
anionic and the cationic ligands, respectively, under MC conditions. Consequently, the 
anionic ligands (Cu-APC and Hemin) robustly inhibited telomerase activity even with 
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MC; in contrast, the inhibition of telomerase caused by cationic TMPyP4 was 
drastically reduced by MC. These results indicate that the binding of 
G-quadruplex-ligands to G-quadruplex via non-electrostatic interactions is preferable 
for telomerase inhibition under physiological conditions. Collating all these results, it is 
reasonable to support that anionic ligands such as Cu-APC are promising anticancer 
drug candidates that efficiently inhibit telomerase activity even in cell nuclei. 
1.2. Development of an Assay for Telomerase Activity without False Negative Results 
(Main Paper 3) 
TRAP assay, which is a most widely-used telomerase assay, can detect telomerase 
activity with high sensitivity, because it amplifies telomerase reaction products by 
polymerase chain reaction (PCR). However, this assay is susceptible to PCR inhibitors 
in clinical samples, which include bile acid, bilirubin, heparin, and hemoglobin. Since 
such reaction inhibition by these inhibitors causes false negative results, TRAP assay 
should not be appropriate for clinical applications. Thus, the author developed a 
telomerase assay without false negative results, which is based on asymmetric PCR 
(A-PCR) on magnetic beads (MBs) and subsequent application of cycling probe 
technology (CPT). In this assay, the telomerase reaction products are immobilized on 
MBs, which are then washed to remove PCR inhibitors in clinical samples. The 
guanine-rich sequences (5’-(TTAGGG)n-3’) of the telomerase reaction products on 
MBs are then preferentially amplified by A-PCR, and the amplified products are 
subsequently detected via CPT. In CPT, a probe RNA with a fluorophore at the 5’ end 
and a quencher at the 3’ end is hydrolyzed by RNase H in the presence of the target 
DNA. The catalyst-mediated cleavage of the probe RNA enhances fluorescence from 
the 5’ end of the probe. Furthermore, the reactions including hybridization and 
hydrolysis of the probe RNA occur repetitively, which leads to fluorescence signal 
amplification. The assay successfully enabled detection of HeLa cells selectively over 
normal human dermal fibroblast (NHDF) cells. Importantly, this selectivity produced 
identical results with regard to detection of HeLa cells in the absence and presence of 
excess NHDF cells; therefore, this assay can be used for practical clinical applications. 
The lower limit of detection for HeLa cells was 50 cells, which is lower than that 
achieved with conventional TRAP assays. The present assay also eliminated false 
negative results caused by PCR inhibitors such as bile salt, heparin, and hemoglobin. 
Furthermore, it was shown that this assay is appropriate for screening among 
G-quadruplex-ligands to find those that inhibit telomerase activity. Therefore, the 
present assay should make a contribution to not only cancer diagnosis but also 
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development of new anticancer drugs. 
1.3. Short Summary 
Telomerase has not been detected in various normal somatic cells except proliferating 
progenitor cells and stimulated lymphocytes despite of the high activity in almost of all 
cancer types including cancer stem or stem-like cells. Thus, telomerase is promising as 
a target for anticancer therapy and cancer diagnosis. Through this thesis, it was 
elucidated that anionic functional groups of G-quadruplex-ligands contribute to 
G-quadruplex-binding and telomerase-inhibiting capacity of the ligands under abundant 
dsDNA condition and MC conditions. These results imply that anionic 
G-quadruplex-ligands can be promising candidates of anticancer drugs. Also, the 
present telomerase assay utilizing A-PCR on MBs and CPT technology was developed. 
This assay allowed high-sensitive detection of cancer cells without false negative results 
caused by PCR inhibitors. Consequently, the findings in this thesis should make a 
contribution to anticancer therapy without side-effects and accurate cancer diagnosis 
targeting telomerase. 
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2. Introduction 
Cancer threatens human health via uncontrolled cell proliferation, invasion, and 
metastasis. Cancer has the highest risk for death among diseases and the number of 
deaths from cancer reached more than 20,000 a day in the world according to World 
Health Statistics by World Health Organization (WHO) (Fig. 2-1). For reduction of the 
death number from cancer, fairly extensive studies have been done. Especially, in 
1980’s molecular biological studies on many cancer-related genes such as oncogens and 
tumor suppressor genes made a huge contribution to elucidation of a carcinogenesis 
mechanism. Oncogenes, which are related to signal transduction promoting cell growth, 
are categorized into viral oncogenes and cellular oncogenes. Expression of cellular 
oncogenes is adequately controlled under normal conditions. However, point mutation, 
translocation, and amplification of those genes abnormally activate or amplify the 
expressed proteins, leading to carcinogenesis. Viral oncogenes are also host cell-derived 
genes that contain mutations or abnormally activated by viral promoters. In contrast to 
oncogenes, tumor suppressor genes usually play a role in inhibition of carcinogenesis by 
involving inhibition of cell divisions, and induction of DNA repair and apoptosis. Thus, 
mutations that reduce functions and expression levels of tumor suppressor genes induce 
carsinogenesis. It has been thought that at least several mutations of cancer-related 
genes are required for human cancer iniciation. For example, mutations of BRCA1 and 
BRCA2 genes, which are tumor suppressor genes, increase an incidence of breast 
cancer to 85%. Thus, an affordable technology for accurate detection of such mutations 
should be greatly-helpful to expect the incidence. The author succeeded in an 
electrochemical genotyping of mutations by developping a novel allele-spcific primer 
extenstion technology, and an electrochemical detection technology for pyrophosphate, 
Fig. 2-1. The worldwide top 5 causes of death (2008) from WHO report. 
0
2
4
6
8
10 > 20000 deaths / day in the world
7.5
D
ea
th
s 
in
 
m
illi
on
s 
/ y
ea
r
 6 
which is produced during a primer extension reaction (Fig. 2-2A) [1]. Furthermore, a 
µ-total analysis sytem (µ-TAS) chip utilizing these technologies allowed accurate 
genotyping in one hour from several µL of blood (Fig. 2-2B) [2, 3]. In the future, this 
device should contribute to low-cost and accurate diagnosis of the cancer incidence. 
 
2.1. Structure and Function of Telomeric DNA 
There can be no doubt about that oncogenes and tumor suppressor genes are 
important triggers for carcinogenesis. However, the mutations of these genes are not 
sufficient factors for carcinogenesis. Immortal cell growth is an essential event for 
carcinogenesis, and is regurally controlled by telomeres at ends of chromosme and 
telomerase catalyzing a telomeric DNA extension. In this section, the structural and 
functional features of telomeres will be explained. 
Telomeres at ends of eukaryotic chromosomes contain telomeric DNA with tandem 
repeats of a G-rich motif (Fig. 2-3) [4-7]. The sequence of the G-rich motif and the 
number of repeats varies among species, from a fixed 4.5 repeats of 5’-TTTTGGGG-3’ 
in the ciliate Oxytricha nova to ~350-500 bp in Saccharomyces cerevisiae, and variable 
numbers of 5’-TTAGGG-3’ repeats encompassing 10-15 kb in humans and 20-50 kb in 
certain mouse and rat species (Table 2-1) [5-7]. Telomeric DNA further has a structural 
Fig. 2-2. (A) Electrochemical genotyping principle, and (B) electrochemical genotyping chip and 
reader (http://panasonic.co.jp/corp/news/official.data/data.dir/2013/02/jn130214-1/jn130214-1. 
html) 
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feature of the 3’-ends with a single-stranded G-rich overhang called G-tail (Fig. 2-3) 
[6-12]. In humans, the length of the G-tail, 5’-TTAGGG-3’, is 150-250 bases. 
Intrinsically, a linear DNA is recognized as a damaged DNA and the ends are rapidly 
joined via catalysis of various nucleases and DNA ligases. However, chromosomal 
DNA is protected from illicit DNA end-joining events [6, 7, 13, 14], because at least six 
telomeric proteins including telomeric repeat-binding factor 1 (TRF1), TRF2, repressor 
and activator protein 1 (RAP1), TRF1-interacting nuclear protein 2 (TIN2), protection 
of telomeres 1 (POT1) and TPP1, bind to telomeric DNA to form a capped complex 
known as shelterin (Fig. 2-4) [6, 7]. TRF1 and TRF2 directly bind to telomeric dsDNA 
via forming each homodimer [6, 7]. On the other hand, POT1 directly binds to G-tail. 
Fig. 2-4. Shelterin composed of telomeric DNA and accessory proteins. 
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Fig. 2-3. Human telomeric DNA. 
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Table 2-1. Telomeric G-rich sequences. 
Sequences
(5'→3') Species References
TTGGGG Tetrahymena thermophila
TTAGGG Human
TTTAGGG Arabidopsis thaliana
TTTTGGGG Oxytricha nova
TTTTGGGG Stylonychia lemnae
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TIN2 forms a bridge between TRF1, TRF2, and TPP1, and TPP1 forms another bridge 
between TIN2 and POT1 [6, 7]. RAP1 homologue in humans associates with telomeric 
DNA via its interaction with TRF2 [6, 7]. 
Telomeric DNA can form an alternative structure termed Telomere loop (T-loop) (Fig. 
2-5) [15]. T-loop is a lariat-like configuration, in which the G-tail invades the dsDNA 
region to form D-loop. Since T-loop is not thermodynamically favorable, the telomeric 
accessory proteins should be implicated in the formation. This structure may be also 
another option to protect chromosomal DNA. 
 
Telomeric DNA is responsible for not only the protection of chromosomal ends but 
also a control of cell life time. During S-phase of the cell cycle, chromosomal DNA is 
replicated from RNA primers by DNA polymerase, and then RNA primers are removed 
by exonuclease (Fig. 2-6A). Thus, daughter strands are shorter than parent strands. This 
end replication problem causes lost of 50-100 bp of telomeric DNA with every cell 
division in normal somatic cells. The shortening of telomeric DNA finally leads to 
inefficiency of the protection of chromosome ends by telomeric DNA (Fig. 2-6B) [16]. 
Furthermore, this deprotection results in end-to-end fusions of chromosomal DNA, 
which causes apoptosis [16]. A series of  these biological events serves as a huge 
barrier to carcinogenesis. Even though oncogenic mutations occur, carcinogenesis 
Fig. 2-6. (A) End replication problem and (B) loss of telomeric DNA with every cell division. 
5’
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RNA primerParent strand Daughter strand
Telomeric DNA Telomeric DNA
Chromosomal DNA
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A                                     B 
Fig. 2-5. Structure of T-loop. 
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should be prevented as long as telomeric DNA shortens in a normal way. 
2.2. Structure and Function of Telomerase 
Not only tumor cells but also germ cells and stem cells can proliferate indefinitely 
[17, 18]. These immortalized cells solve the end replication problem by telomeric DNA 
extension using telomerase (Fig. 2-7A) [19-22]. Telomerase has a complex structure 
composed of many subunits, but not all of them are well-understood. Previous studies 
showed that two subunits, which are found in a central part of a human telomerase 
holoenzyme, have critical functions in telomeric DNA extension [23-26]. One of the 
subunits is telomerase reverse transcriptase (abbreviated to TERT, or hTERT in humans), 
which can synthesize DNA using RNA template (Fig. 2-7A) [23, 24]. Another subunit is 
a telomerase RNA component (abbreviated to TR, or hTR in humans) including a 
template sequence for telomeric DNA extension (Fig. 2-7A) [25, 26]. TR is involved at 
multiple stages of telomerase biogenesis and function. For example, TR provides a 
template boundary element that limits the extent of reverse transcription. In humans, 11 
nucleotides of hTR, 5’-CUAACCCUAAC-3’, hybridize with G-tail and serve as the 
template for the extension reaction from the hybridized G-tail (Fig. 2-7A). As a result, 
Fig. 2-7. (A) Telomeric DNA extension by telomerase and (B) crystal structural analysis of TERT 
of Tribolium castaneum with RNA-DNA hairpin of putative hTR (Yellow) and telomeric DNA 
(Gray) (PDB ID: 3KYL) [28]. 
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new six nucleotides, 5’-GGTTAG-3’, are added at the 3’-end of telomeric DNA (Fig. 
2-7A). Crystal structural studies on Tribolium castaneum TERT and Tetrahymena 
telomerase holoenzyme in 2008, 2010, and 2013, respectively, strongly supported these 
reaction mechanisms including hybridization and addition of the six nucleotides [27, 28, 
29]. These studies demonstrated that TERT consists of three highly conserved domains, 
organized into a ring-like structure, and the structure has an interior cavity, which is 
large enough for RNA/DNA duplex to dock in (Fig. 2-7B) [27, 28, 29].  
Importantly, in 85-90 % of human tumor cells, telomerase is highly activated [22]. 
Antisense RNA can inhibit the telomerase activation in tumor cells [30]. For example, 
antisence RNA of hTR competitively prevented human telomerase from binding to 
telomeric DNA by binding to hTR [30]. This competitive prevention caused reduction 
in telomerase activity, and then tumor cells stopped proliferation in 23 to 26 days. A 
dominant-negative mutant of hTERT also inhibited proliferation of tumor cells [30]. 
These results indicate that constituous telomerase activation is essential for 
carcinogenesis as well as activation and inactivation of oncogenes and tumor supressor 
genes, respectively. More importantly, most of normal cells excepting germ cells, stem 
cells, and activated lymphocytes show little or no telomerase activity [17, 18, 31]. The 
specificity and universality of the telomerase activity for cancer cells implies two 
important suggestions: (i) inhibition of the telomerase activity should allow an 
anticancer therapy without any side effects, and (ii) detection of the telomerase activity 
should allow a precise cancer diagnosis.  
2.3. Telomerase Inhibition by G-Quadruplex 
In association with the demonstration of telomeric DNA extension by telomerase, a 
significant finding was reported that telomeric DNA can form a non-canonical DNA 
structure termed G-quadruplex (Fig. 2-8A) [32, 33]. G-quadruplex is a four-stranded 
DNA structure with stacked guanine tetrads, G-quartets, which are held together via 
eight Hoogsteen hydrogen bonds (Fig. 2-8A). The existence and possible structure of 
G-quartets was proposed about 50 years ago [34]. Since then, G-quadruplexes formed 
by various G-rich sequences have been reported [32, 33, 35-45]. Structural studies of 
G-quadruplexes have demonstrated that the G-rich sequences can form highly 
polymorphic G-quadruplexes, and the variation in these structures depends on the 
sequences and the experimental conditions (e.g., coexisting metal ion, metal ion 
concentration, and degree of molecular crowding) (Fig. 2-9) [46-66]. Among these 
polymorphic G-quadruplexes, G-quadruplexes formed by human telomeric DNA, in 
particular, have been investigated extensively, because G-quadruplex DNA inhibits 
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telomerase activity by preventing telomerase from binding to telomeric DNA (Fig. 
2-8B) [67]. This finding indicates that G-quadruplex-ligands that inhibit telomerase 
activity via induction or stabilization of G-quadruplex are promising candidates of 
anticancer drugs without side effects. Thus, development of G-quadruplex-ligands has 
become an area of great interest. Moreover, recent bioinformatic studies showed that 
about 370,000 putative G-quadruplex-forming sequences exist throughout the human 
genome [68, 69]. Many of the putative G-quadruplex-forming sequences are enriched in 
promoter regions of oncogenes, including c-MYC, c-kit, HRAS, and KRAS [53, 
Fig. 2-8. (A) G-quadruplex formation by human telomeric DNA and (B) telomerase inhibition by 
G-quadruplex in tumor cells. 
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70-88]. These bioinformatic studies strongly indicate that G-quadruplexes can influence 
carcinogenesis by modulating transcription of oncogenes (Fig. 2-10). Importantly, some 
G-quadruplex-ligands regulate the expression of these oncogenes by binding to 
G-quadruplexes in the promoter regions [70-76, 78, 80, 82, 86, 88]. Thus, ligands that 
recognize and bind to G-quadruplexes in telomeric DNA and/or promoter regions of 
oncogenes are promising anticancer drugs. 
2.4. G-Quadruplex-Ligand as Anticancer Drug 
Many G-quadruplex-ligands developed to date contain a π-planar structure, of which 
size is similar to that of G-quartet, because the plane aromatic surface is essential for 
making strong π-π stacking interactions with G-quartet (Fig. 2-11) [89-91]. Most of 
Coding regionPromoter region
Transcription
Altered
transcription
Fig. 2-10. Transcriptional regulation by G-quadruplex. 
Fig. 2-9. G-quadruplex polymorphism depending on sequences and metal ions. 
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them further contain cationic functional groups in order to form electrostatic attractive 
interactions with G-quadruplex (Fig. 2-11) [89-91]. One of the most extensively studied 
G-quadruplex-ligands is 5,10,15,20-tetra(N-methyl-4-pyridyl)porphyrin, TMPyP4 (Fig. 
2-11) [89-97]. This cationic porphyrin derivative is composed of four modified pyrrol 
units and four cationic functional groups. Based on results from UV titration experiment, 
NMR, and photocleavage assay, Hurley’s group reported for the first time that TMPyP4 
bound to a human telomeric oligo G-quadruplex [92]. Other groups also showed that 
TMPyP4 bound to the G-quadruplex with multiple binding modes (Fig. 2-12A) [80, 98]. 
It was further demonstrated that TMPyP4 inhibited telomerase activity in a cell-free 
system [92]. TMPyP4 inhibits proliferation of various tumor cells including human 
pancreatic, breast, and prostate carcinomas. Furthermore, TMPyP4 can 
TMPyP4G-quartet Cu-TMPyP4
N
N N
N
N
N
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N
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N N
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Fig. 2-11. Chemical structures of G-quartet and cationic G-quadruplex-ligands. 
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downregulate the expression of oncogenes like C-MYC, VEGF, and K-RAS [74-76, 78, 
80, 82, 89, 99, 100]. Similarly, it has been shown that other cationic 
G-quadruplex-ligands such as BRACO-19 [101], 12459 [102], and PIPER [103] also 
inhibit the telomerase activity by binding the telomeric G-quadruplex. However, 
TMPyP4 inhibits growth of not only cancer cells but also normal cells [104]. This 
non-specific antiproliferative capacity of TMPyP4 is attributable to non-specific binding 
of TMPyP4 with dsDNA (Fig. 2-12B) [105-108]. TMPyP4 can bind to dsDNA 
non-specifically because the cationic functional groups interact with anionic phosphate 
groups of dsDNA electrostatically. Thus, many cationic ligands including TMPyP4 
should bind to dsDNA region of chromosomal DNA even in normal cells, which may 
lead to antiproliferative effect on normal cells. In addition, most of cationic 
G-quadruplex-ligands with highly efficient telomerase inhibition in vitro showed low 
anticancer effects in cellular assays [18-20]. This reduced effect may be because living 
cells contain various macromolecules, of which concentrations reach 400 g/L [109-111], 
although diluted solutions are usually used for test tube experiments. Such 
high-concentrated biomolecules in cells, which is known as molecular crowding (MC) 
[109-111],
 
have an impact on various reactions involving biomolecules by affecting 
several aspects to a solution in cells, such as a decrease in dielectric constant [110] and 
water activity [59, 64, 112, 113], and an increase in viscosity [114] and excluded 
Fig. 2-12. Structural analysis of binding TMPyP4 with parallel G-quadruplex formed by human 
telomeric DNA (A) and dsDNA (B). 
PDB ID: 2HRI 
A                                    B 
PDB ID: 1EM0 
Top view 
Side view 
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volume [115]. Previous studies on interaction between dsDNA and its cationic ligands 
showed that almost all of the ligands acquire a significant number of water molecules 
upon binding to dsDNA (Table 2-2) [116-121]. Under a condition of decreased water 
activity caused by MC, uptake of water molecules is unfavorable and thus the affinity of 
the ligands with dsDNA are drastically reduced. More importantly, it was recently 
reported that cationic G-quadruplex-ligands including TMPyP4, BMVC, and Hoechst 
33258 reduced their binding affinity to the telomeric G-quadruplex and the subsequent 
telomerase inhibitory effect under MC conditions due to uptake of water molecules 
upon binding to the G-quadruplex [122].  
2.5. Telomeric Repeat Amplification Protcol (TRAP) Assay 
In most human tumor cells, telomerase is highly-activated and plays a key role of the 
immortal cell proliferation, although the activity has not been detected in various 
Table. 2-2. The number of water molecules (∆nw) released upon the binding of ligand to dsDNA 
DNA sequence DNA structure Ligand Cosolute ∆n w Reference
Calf thymus  DNA dsDNA Ethidium Sucrose (Triethylene glycol,
Betaine) -0.25 116, 117
Propidium Sucrose (Triethylene glycol,
Betaine) -6.4
Proflavine Sucrose (Triethylene glycol,
Betaine) -30
Daunomycin Sucrose (Triethylene glycol,
Betaine) -18
7-aminoactionomycin D Sucrose (Triethylene glycol,
Betaine) -32
d(CGCGCAATTGCGCG)2 dsDNA Hoechst 33258 Triethylene glycol -78 118
Acetamide -51
Betaine -51
Tetraethylene glycol -67
d(CGCGCAATTGCGCG)2 dsDNA DAPI Triethylene glycol
(Actamide, Betaine,
Trimethylamine N-oxide)
-35 119
Netropsin Triethylene glycol
(Actamide, Betaine,
Trimethylamine N-oxide)
-26
Pentamidine Triethylene glycol
(Actamide, Betaine,
Trimethylamine N-oxide)
-34
Calf thymus  DNA dsDNA Daumocycin Sucrose (Triethylene glycol,
Betaine) -17.8 120
Adriamycin Sucrose (Triethylene glycol,
Betaine) -35.8
Calf thymus DNA dsDNA Triethylene glycol -74 121
Sucrose -30
d(GGGTTA)3GGG G-quadruplex TMPyP4 Glycerol -30 122
Hoechst 33258
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normal somatic cells [22, 31]. Thus, telomerase has been suggested as a promising 
marker for cancer diagnosis. Several studies showed the association between telomerase 
activity and a number of prognostic and clinopathological features in colorectal cancer 
[123-129]. For the diagnosis with the telomerase activity as a marker, the assay for the 
telomerase activity, which is precise and sensitive, is required. 
A conventional procedure for telomerase activity assay is TRAP assay (Fig. 2-13) 
[22]. In the assay, a telomerase reaction is carried out using biological samples such as 
Fig. 2-13. TRAP assay. 
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cell lysate including telomerase, and a telomerase substrate primer. Following the 
telomerase reaction, the reaction products are amplified by PCR using the telomerase 
substrate primer as a forward primer. Finally, the amplification products are analyzed 
electrophoretically. Because telomerase adds six nucleotides with every extension 
reaction, a ladder of PCR products with six base pair (bp) increments is observed. Given 
simply a principle of TRAP assay, the telomerase substrate primer and a reverse primer 
in PCR should be a telomeric repetitive oligonucleotide and its complementary 
oligonucleotide, respectively. However, such primers generate primer dimers with 
different length because of their repetitive complementary sequences (Fig. 2-14). The 
primer dimers further bind to the primers, leading to longer primer artifacts with six bp 
increments. To avoid the false positive result, TS (telomerase substrate) primer, which is 
a non-telomeric oligonucleotide, is used as the telomerase substrate primer (Table 2-3) 
[22]. In addition, several reverse primers, which have uncomplementary sequences with 
the telomeric sequence, have been designed (Table 2-3) [22, 130-132]. These 
improvements drastically reduce the false positive result. However, TRAP assay still has 
a severe problem that some polymerase inhibitors in clinical samples inhibit PCR, 
which leads to the false negative results [131]. Thus, a novel telomerase assay that can 
avoid the false negative results has been required for practical cancer diagnostics.  
5’-TTAGGG TTAGGG TTAGGG TTAGGG TTAGGG TTAGGG TTAGGG-3’
3’-AATCCC AATCCC AATCCC AATCCC AATCCC AATCCC AATCCC-5’
5’-TTAGGG TTAGGG TTAGGG TTAGGG TTAGGG TTAGGG-3’
3’-AATCCC AATCCC AATCCC AATCCC AATCCC AATCCC-5’
5’-TTAGGG TTAGGG TTAGGG TTAGGG TTAGGG-3’
3’-AATCCC AATCCC AATCCC AATCCC AATCCC-5’
5’-TTAGGG TTAGGG TTAGGG TTAGGG-3’
3’-AATCCC AATCCC AATCCC AATCCC-5’
Forward primer: 5’-TTAGGG TTAGGG TTAGGG TTAGGG-3’
Reverse primer: 3’-AATCCC AATCCC AATCCC AATCCC-5’
+
Fig. 2-14. Example of primer dimmers with different length caused by the telomeric repetitive 
forward primer and its complementary reverse primer. Underlined sequences are elongated 
products via PCR. 
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2.6. Purposes in This Study 
2.6.1. Elucidation of Rules to Design Anticancer Drugs with Efficient Telomerase 
Inhibitory Effect (Main Papers 1 and 2) 
G-quadruplex-ligands should be promising as the anticancer drug candidate without 
side effects. However, most of cationic G-quadruplex-ligands did not show the desired 
anticancer effects in cellular assays despite of their highly efficient telomerase inhibition 
in vitro. Importantly, previous studies on the conventional G-quadruplex-ligands imply 
that cationic functional groups may prevent G-qaudruplex ligands from binding to the 
human telomeric G-quadruplex in cell nuclei because of non-specific interaction with 
dsDNA and uptake of water molecules upon binding, which is unfavorable under the 
condition of decreased water activity. Therefore, an alternative strategy to improve the 
binding efficiency to the G-quadruplex in cell nuclei is required. A possible solution is 
to make the ligand non-ionic or anionic. In fact, a non-ionic ligand, telomestatin [104], 
can bind to the G-quadruplex with remarkable selectivity, whereas non-ionic ligands 
have problems such as low water solubility and difficulty of chemical synthesis. On the 
other hand, few anionic molecules have been investigated for the binding abilities to the 
G-quadruplex and the telomerase inhibitory effects. Thus, in this thesis, in order to 
acquire the strategy to design G-quadruplex-ligands that exert the desired effect even in 
cell nuclei, various cationic and anionic G-quadruplex-ligands were systematically 
examined under cell nuclei-mimicking conditions, in which excess dsDNA and MC 
cosolutes exist. 
2.6.2. Development of an Assay for Telomerase Activity without False Negative 
Results (Main Paper 3) 
Telomerase activity is an ideal target for cancer diagnosis, because it is specifically 
Table 2-3. Primers used in TRAP assay. 
a
 Underlined sequences of reverse primers are uncomplimentary with telomeric repetitive 
sequences. 
Name Function Sequence a Ref.
TS Telomerase substrate primer andforward primer 5'-AATCCGTCGAGCAGAGTT-3' [22]
CX Reverse primer 5'-CCCTTACCCTTACCCTTACCCTAA-3' [22]
CX-ext Reverse primer 5'-GTGCCCTTACCCTTACCCTTACCCTAA-3' [130]
ACX Reverse primer 5'-GCGCGGCTTACCCTTACCCTTACCCTAACC-3' [131]
ACT Reverse primer 5'-GCGCGGCTAACCCTAACCCTAACC-3' [131]
Cxa Reverse primer 5'-GTGTAACCCTAACCCTAACCC-3' [132]
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activated in tumor cells. Thus, TRAP assay can be a critical technique for accurate 
cancer diagnosis. However, TRAP assay is not used for practical cancer diagnostics, 
because it should cause the false negative results. Thus, some research groups have 
developed other telomerase assays based on various sensors or methodologies, such as 
optical fiber [133], magnetic resonance reader [134], magneto-mechanical detector 
[135], ISFET (ion-sensitive field-effect transmitter) [136], electrochemical method 
[137], photonic microring device [138], and surface plasmon resonance method [136, 
139] , but in general such assays do not utilize any signal amplification processes like 
PCR and were therefore less sensitive than TRAP assays. Other groups proposed 
telomerase assays with novel signal amplification processes involving enzymes 
[140-143], DNAzymes [144-146], and nanoparticles [147-150] instead of PCR. 
Although some of these assays with novel amplification reactions detected telomerase 
activity with high sensitivity [140, 143], the enzymes used for catalysis-based 
amplification may also be inhibited by components in clinical samples. Then, in this 
thesis, a novel telomerase assay that can absolutely avoid the false negative results was 
attempted to be developed toward cancer diagnosis without wrong diagnosis. 
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3. Elucidation of Rules to Design Anticancer Drugs with Efficient Telomerase 
Inhibitory Effect 
3.1. Introduction 
Since G-quadruplex DNA inhibits telomerase activity by preventing telomerase 
binding to telomeric DNA [1], development of G-quadruplex-ligands has become an 
area of great interest [2-16]. Many G-quadruplex-ligands developed to date contain a 
π-planar structure, of which size is similar to that of G-quartet, and cationic functional 
groups in order to bind to G-quadruplex via π-π stacking interaction and electrostatic 
attractive interaction, respectively [11-13]. However, most of cationic 
G-quadruplex-ligands with highly efficient telomerase inhibition in vitro showed lower 
anticancer effects in cellular assays [17-19]. This divergence is at least partly due to 
differences between chemical conditions in vitro and in vivo. Living cells contain 
various macromolecules, of which concentrations reach 400 g/L [20-22], despite a 
diluted solution under test tube conditions. Existence of the excess macromolecules 
often leads to unexpected interactions between the drug and the off-target molecules and 
have an impact on several aspects to a solution in cells including a decrease in dielectric 
constant [21] and water activity [23-26], and an increase in viscosity [27] and excluded 
volume [28]. Thus, for the rational design of drugs including G-quadruplex-ligands, one 
should consider how intracellular factors influence their functions. 
At least two intracellular environmental factors should inhibit the properties of 
cationic G-quadruplex-ligands. First, abundant dsDNA found in genome DNA should 
prevent cationic G-quadruplex-ligands from binding to the human telomeric 
G-quadruplex, because positive charges of the cationic ligands also mediate 
high-affinity and non-specific interactions with the dsDNA [29-32]. The diminished 
affinity to the telomeric G-quadruplex should lead to low efficiency for telomerase 
inhibition in cell nuclei. In addition, non-specific interactions of cationic 
G-quadruplex-ligands to the dsDNA in genome DNA probably cause severe toxicity to 
normal cells. Second, high-concentrated biomolecules in cells, which is known as MC 
[20-22], also affect the binding property of cationic G-quadruplex-ligands [33]. It was 
reported that MC reduced the binding affinity of cationic G-quadruplex-ligands 
including TMPyP4 and their telomerase inhibition [33]. This reduction is attributed to 
that water molecules are acquired upon cationic ligands binding to the G-quadruplex 
and the hydration reaction is unfavorable under a decreased water activity condition by 
MC [33]. Therefore, an alternative strategy to improve the telomerase inhibitory effect 
of G-quadruplex-ligands in cell nuclei is required. A possible solution is to make the 
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ligand non-ionic or anionic. In fact, a non-ionic ligand, telomestatin, can bind the 
telomeric G-quadruplex with remarkable selectivity over dsDNA and inhibit 
proliferation of cancer cells efficiently but not normal cells [34]. However, telomestatin 
have less water solubility due to its non-ionic property. In addition, telomestatin is a 
natural compound and difficult to synthesize chemically. On the other hand, few anionic 
molecules have been investigated for the binding abilities to the G-quadruplex and the 
telomerase inhibitory effects. 
Herein, in order to develop G-quadruplex-ligands that exert desired functions in cell 
nuclei, G-quadruplex-binding and telomerase-inhibiting capacity of eight 
G-quadruplex-ligands was systematically examined: three cationic, TMPyP4 (Fig. 2-11) 
[3-5, 10-14, 35], copper-coordinating TMPyP4 (Cu-TMPyP4; Fig. 2-11), and PIPER 
(Fig. 2-11) [36]; and five anionic, Cu-APC (Fig. 3-1), nickel(II) phthalocyanine 
tetrasulfonic acid, tetrasodium salt (Ni-APC; Fig. 3-1), phthalocyanine tetrasulfonate 
hydrate (APC; Fig. 3-1), Hemin (Fig. 3-1) [37], and 
5,10,15,20-tetraphenyl-21H,23H-porphine-p,p′,p″,p′′′-tetrasulfonic acid, tetrasodium 
hydrate (TS4; Fig. 3-1) [30]. Experimental conditions included excess decoy dsDNA or 
molecular crowding cosolutes. 
3.2. Materials and Methods 
3.2.1. Materials 
Fig. 3-1. Anionic G-quadruplex-ligand candidates used in this study. 
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High-performance liquid chromatography (HPLC) purification grade DNA 
oligonucleotides were purchased from Tsukuba Oligo Service Co., Ltd. (Ibaraki, Japan). 
Cu-APC, Ni-APC, APC, and TS4 were purchased from Sigma-Aldrich (St. Louis, MO, 
USA) and were used without further purification. TMPyP4, PIPER, and Hemin were 
purchased from Dojindo Laboratories (Kumamoto, Japan), Merck KGaA (Darmstadt, 
Germany), and Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan), respectively, and 
were used without further purification. Cu-TMPyP4, a Cu2+ derivative of TMPyP4, was 
synthesized as follows. A 101.7 mg (0.15 mmol) sample of TMPyP4 was dissolved in 
40 mL of freshly distilled water, and the solution was heated to reflux. 6.65 g (50 mmol) 
of CuCl2 was added to the resulting solution, and the mixture was allowed to continue 
refluxing for 2 h with vigorously stirring. The reaction mixture was cooled below 4 °C, 
then the excess amount of sodium perchlorate was added to precipitate the Cu-TMPyP4. 
The resulting mixture was allowed to stand overnight below 0 °C. The precipitate was 
filtered and washed several times with dilute perchloric acid. Ethylene glycol (EG), poly 
ethylene glycol with an average molecular weight of 200 (PEG 200), and poly ethylene 
glycol with an average molecular weight of 8000 (PEG 8000) were purchased from 
Wako Pure Chemical Industries Ltd. (Osaka, Japan), and were used without further 
purification. To generate stock solutions for each ligand, Cu-APC, Ni-APC, APC, 
TTMAPP, TS4, TMPyP4, and Cu-TMPyP4 were dissolved in distilled water, and 
PIPER and Hemin were dissolved in 3% CH3COOH and 10 mM NaOH, respectively. 
3.2.2. Circular Dichroism (CD) Spectroscopy 
CD experiment for 20 µM human telomeric oligo DNA, 5’-(GGGTTA)3GGG-3’ 
(Htelo-DNA) in a buffer containing 50 mM MES-LiOH (pH 7.0) and 100 mM KCl was 
carried out using a J-820 spectropolarimeter (JASCO Co., Ltd., Hachioji, Japan) with a 
0.1-cm path-length quartz cell at 25°C. The CD spectrum was obtained by taking the 
average of three scans made at 0.5-nm intervals from 200 to 350 nm. Before 
measurement, the DNA sample was heated at 80°C for 2 min, gently cooled at 2°C 
min-1.  
3.2.3. Binding Assay 
Absorbance for ligands including TMPyP4 (1.0 µM), Cu-APC (2.5 µM), Ni-APC 
(2.5 µM), APC (2.5 µM), Cu-TMPyP4 (1.0 µM), PIPER (10 µM), Hemin (12.5 µM) or 
TTMAPP (1.0µM) with various concentrations of Htelo-DNA was recorded at 20°C or 
25°C; a UV-1700 spectrophotometer (Shimadzu) connected to a Shimadzu TMSPC-8 
thermoprogrammer (Shimadzu) was used with a 1.0-cm path-length quartz cell. The 
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measurements for these ligands were carried out in a buffer containing 50 mM 
MES-LiOH (pH 7.0) and 100 mM KCl in the absence or presence of 128 µg/ml λ DNA 
or cosolute (0–40 wt% EG, 0–40 wt% PEG 200 or 0–20 wt% PEG 8000). Exceptionally, 
the buffer further comprised CH3COOH (0.25% or 1.5%) or NaOH (2 mM) for the 
measurements for PIPER or Hemin, respectively. Before measurement, each sample 
was heated to 80°C for 2 min and gently cooled to 25°C at 2°C min-1. 
3.2.4. Stoichiometric Titration Assay 
Absorbance at 690 nm for Cu-APC (100 µM) with 0-500 µM Htelo-DNA was 
recorded at 25°C; a UV-1700 spectrophotometer (Shimadzu) connected to a Shimadzu 
TMSPC-8 thermoprogrammer (Shimadzu) was used with a 0.1-cm path-length quartz 
cell. The measurement was carried out in a buffer containing 50 mM MES-LiOH (pH 
7.0), 100 mM KCl, and 10 mM MgCl2. Before measurement, each sample was heated to 
80°C for 2 min and gently cooled to 25°C at 2°C min-1. 
3.2.5. Evaluation of the Association Constant 
The fractional degree (ν) of saturation of each ligand-binding site to DNA can be 
expressed by the following equation based on the model that is based on the assumption 
of one binding site to estimate the equilibrium parameters [38]: 
[ ] [ ] [ ] [ ]( ) [ ][ ]{ } [ ]ligand2/DNAligand4DNAligandDNAligand 2dd −++−++= KKν              (1) 
where Kd is the dissociation constant, [DNA] is the concentration of DNA, and [ligand] 
is the concentration of the ligand. Equation (1) can be transformed into equation (2). 
The association constant (Ka) for each DNA for each ligand was determined with 
equation (2): 
[ ] [ ] [ ] [ ]( ) [ ][ ]{ } [ ] bKKKKKKa +−++−++= ligand2/DNAligand41DNAligand1DNAligand a2a2aaaaθ   (2) 
where θ is the absorbance value, Ka is the apparent association constant of DNA binding, 
a is a scale factor, and b is the initial θ value. 
3.2.6. Determination of the Number of Water Molecules Released upon 
G-Quadruplex/Ligand Complex Formation 
3.2.6.1. Theoretical Equation  
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Formation of a G-quadruplex/ligand complex in a solution containing a cosolute (e.g., 
PEG 200) and a cation (e.g., K+) can be represented as follows: 
where CS and M+ represent a cosolute and cation, respectively. ∆nw, ∆ncs, and ∆nM+ 
represent the numbers of water molecules, cosolute molecules, and cations, respectively, 
that are released upon the complex formation. The observed equilibrium constant (Ka) 
for the complex formation is: 
+
+
∆∆∆
= M
CSw
MCSwa0
nnn
aaaKK                                              (5) 
where K0 is the true thermodynamic equilibrium constant, and aw, acs, and aM+ are the 
activities of water, the cosolute, and the cation, respectively. At a constant temperature 
and pressure, the first derivatives of ln Ka by ln aw are represented by the following 
equation [23-25]. 
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3.2.6.2. Experimental Procedure 
(i) The observed equilibrium constants for the formation of the G-quadruplex/ligand 
complexes were measured in the absence and presence of various amounts (10, 20, 
30, and 40 wt%) of cosolute (e.g., PEG 200) at a constant cation concentration. 
(ii) The water activity was determined using a vapor phase osmometer or a freezing 
point depression osmometer at room temperature under the assumption that 
cosolutes do not directly interact with DNA. Although the osmotic pressure values 
for most cosolutes can be measured using a vapor phase osmometer, the osmotic 
pressure of cosolutes (cosolvents) with boiling points less than 100°C should be 
obtained using a freezing point depression osmometer. In contrast, the freezing 
point depression osmometer is unsuitable for osmotic pressure measurements of 
high molecular weight cosolutes because solutions containing high molecular 
weight cosolutes sometimes do not freeze uniformly. 
A model 5520XR pressure osmometer (Wescor Inc., Logan, UT, USA) and the 
osmotic stressing method were used to measure via the vapor phase the osmotic 
+
+∆+∆+∆+− MCSOH/ligandquadruplexG MCS2w nnnLigandquadruplexG +− (4) 
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pressure for EG, PEG 200, and PEG 8000. 
(iii) In calculating the water activity from the osmotic pressure, it was assumed that the 
temperature dependence of the water activity was small between 25 and 80°C; this 
assumption has been confirmed experimentally. The logarithm of water activities 
(aw) was calculated from the measured osmolality (mmol kg-1) with the following 
equation: 
( ) ww aMRT ln/=ψ                                                                          (7) 
where Ψ is the water potential, Mw is the molecular weight of water (0.018 kg/mol), 
R is the gas constant (8.314 J mol-1 K-1), and T is the temperature in Kelvin. The 
relationship between water potential (MPa) and osmolality (mmol kg-1), in the cases 
where the water potential is independent of temperature, was calculated using the 
following equation: 
400/osmolality −=ψ                                               
 
(8) 
(iv) The values of ln Ka at 25°C at different cosolute concentrations were plotted on the 
y-axis and the values of ln aw for each solution were plotted on the x-axis. 
For example, the stability (ln Ka) of G-quadruplex/TMPyP4 complex decreased 
linearly with the decrease in ln aw. Although the slope of the plot included two 
variable terms responsible for the cosolute and cation bindings, the linear plot 
(described by eq. 6) indicated that these variable terms were insignificant, and the 
slope approximately equaled the constant term –∆nw. If the slope of the linear plot 
was positive, water molecules were taken up upon formation of the 
G-quadruplex/ligand complex; if the slope was negative, water molecules were 
released during complex formation. 
3.2.7. Two-Step TRAP Assay 
The two-step telomere repeat amplification protocol (tsTRAP) assay was improved 
on the basis of the manufacturer’s protocol for the TRAPEZE telomerase detection kit 
manufactured by Millipore Corporation (Billerica, MA, USA) [39, 40]. In the tsTRAP 
assay, the telomerase reaction mixture containing G-quadruplex-ligand was first diluted 
and then used as a template for the PCR step described below. Thus, diluted 
G-quadruplex-ligand did not affect PCR efficiency. Each 10-µL telomerase reaction 
mixture contained telomerase, 1× TRAP reaction buffer, 1× dNTP mix, and 0.2 µL TS 
primer, and either lacked G-quadruplex-ligand or contained 2 µL of a defined 
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concentration of G-quadruplex-ligand. In the first step, each reaction was incubated at 
30°C for 60 min; each mixture was then heated at 90°C for 10 min. In the second step, 
telomerase reaction products were amplified in a 10-µL PCR reaction mixture 
containing 50-fold diluted telomerase mixture, 0.2 µL TS primer, 0.2 µL TRAP primer 
mix, 1× dNTP mix, 1× LA Taq polymerase buffer, and LA Taq polymerase 
manufactured by Takara Bio Inc. (Shiga, Japan); the PCR was carried out over 30 cycles 
each comprising denaturation at 94°C for 30 s, annealing at 59°C for 30 s, and extension 
at 72°C for 30 s. The TRAP assay products were resolved by non-denaturing 
electrophoresis at 400 V through a 10% nondenaturing polyacrylamide gel in 
Tris-borate-EDTA buffer (pH 8.5). The gels were stained with GelStar nucleic acid gel 
stain manufactured by Cambrex Corporation (East Rutherford, NJ, USA), and imaged 
using FLS-5100 film manufactured by Fujifilm Corporation (Tokyo, Japan). Telomerase 
activity was measured according to the protocol provided with the TRAPEZE 
telomerase detection kit. For the negative control reactions, lysis buffer was added in 
the place of telomerase. For the positive control reactions, telomerase extract was added 
to a reaction solution that lacked any G-quadruplex-ligand. Relative activity (A) was 
calculated via the following equation: 
( ){ } ( ){ }pp CXXCXXA /// 00 −−=                                         (3) 
where X is the signal intensity of the region of the gel lane corresponding to the TRAP 
product ladder bands and C is the signal intensity of the region of the gel lane 
corresponding to the internal control product. Subscripts “p” and “0” indicate the 
positive and negative controls, respectively. 
3.3. Results 
3.3.1. Excess dsDNA Effects on Functional Capacities of G-Quadruplex-Ligands 
3.3.1.1. Effects of Excess dsDNA on Binding Capacities 
Selectivity to G-quadruplex over dsDNA is essential for G-quadruplex-ligands, 
because a non-specific binding of G-quadruplex-ligands to a part of genomic DNA that 
forms dsDNA not only reduces their binding efficiency to G-quadruplex but also causes 
side effects. To study the selectivity of Cu-APC (Fig. 3-1), the binding affinity of 
Cu-APC was evaluated by UV-Vis titration with an annealed human telomeric oligo 
DNA, 5’-GGG(TTAGGG)3-3’ (Htelo-DNA); dsDNA, 
5’-AGAAGAGAAAGA-3’/5’-TCTTTCTCTTCT-3’ (DS-DNA); and ssDNA, 5’-T21-3’ 
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 (SS-DNA) in a buffer containing 50 mM MES-LiOH (pH 7.0) and 100 mM KCl at 
25°C. Under this condition, Htelo-DNA showed a CD spectrum with a positive peak 
and a negative peak at 295 nm and 240 nm, respectively.  This result indicates that 
Htelo-DNA formed a (3+1) G-quadruplex (Fig. 3-2) [41-43]. A new peak around 690 
nm in the Q band increased as a function of Htelo-DNA concentration (Fig. 3-3A), 
which indicates that Cu-APC bound to the G-quadruplex formed by Htelo-DNA. 
Furthermore, the stoichiometry was studied with higher concentrations of Cu-APC and 
Htelo-DNA (100 µM Cu-APC and 0-500 µM Htelo-DNA) in a buffer containing 50 mM 
MES-LiOH (pH 7.0), 100 mM KCl, and 10 mM MgCl2. MgCl2 was added into the 
buffer because Mg2+ reduces the electrostatic repulsion between Cu-APC and DNA, 
resulting in a higher affinity of Cu-APC with Htelo-DNA. A stoichiometric point around 
100 µM Htelo-DNA was observed (Fig. 3-4), suggesting a 1:1 binding of Cu-APC and 
Htelo-DNA. Based on the assumption that the 1:1 binding stoichiometry does not 
depend on the experimental conditions, the absorbance at 690 nm was plotted against 
the concentration of Htelo-DNA (Fig. 3-3B) and the Ka value for Htelo-DNA was 
determined to be (2.4 ± 0.2) × 104 M-1 at 25°C (see 3.2.5. Evaluation of the association 
constant). Notably, in contrast to Htelo-DNA, the Ka values for DS-DNA and SS-DNA 
could not be determined because of the small change in the peak at 690 nm with 
addition of DS-DNA or SS-DNA (Fig. 3-3B). These results demonstrate the 
significantly high selectivity of Cu-APC to the G-quadruplex. 
To obtain further insight into the selectivity of Cu-APC to the G-quadruplex, UV-Vis 
titrations in the presence of λ DNA, which is a double-stranded DNA isolated from 
bacteriophage λ and 48502 base pairs in length, corresponding to 400 µM in base 
Fig. 3-2. CD spectrum of 20 µM Htelo-DNA in a buffer containing 50 mM MES-LiOH (pH 7.0) 
and 100 mM KCl at 25°C. 
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units were conducted. Increase in the same peak at 690 nm in the presence of λ DNA 
demonstrated that Cu-APC bound to the G-quadruplex with the Ka value of (2.5 ± 0.2) × 
104 M-1 at 25°C (Fig. 3-3B), which is almost the same as that in the absence of λ DNA. 
These results suggest that excess dsDNA has no effect on the binding properties of 
Cu-APC to the G-quadruplex. Furthermore, the Ka values of Ni-APC (Fig. 3-1), a 
nickel-coordinating anionic phthalosyanine, for Htelo-DNA in the absence and the 
Fig. 3-4. Change in absorbance at 690 nm of 100 µM Cu-APC with 0-500 µM Htelo-DNA in a 
buffer containing 50 mM MES-LiOH (pH 7.0), 100 mM KCl, and 10 mM MgCl2 at 25°C. 
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Fig. 3-3. Cu-APC binding to G-quadruplex with high selectivity. (A) UV-Vis spectra of Cu-APC 
with Htelo-DNA (0, 0.1, 0.2, 0.5, 1, 2, 5, 10, 25, 100 or 250 µM) in a buffer containing 50 mM 
MES-LiOH (pH 7.0) and 100 mM KCl at 25°C. (B) Plots of absorbance at 690 nm of Cu-APC as 
a function of Htelo-DNA, SS-DNA and DS-DNA in the absence of λ DNA, and Htelo-DNA in 
the presence of λ DNA.  
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presence of λ DNA were (1.8 ± 0.3) × 104 M-1 and (1.4 ± 0.1) × 104 M-1 at 20°C, 
respectively (Fig. 3-5). These results were similar to those with Cu-APC, suggesting 
that the binding properties of anionic phthalocyanines to the G-quadruplex are 
independent of the coordinating metal.  
Next, the binding affinity of a cationic porphyrin, TMPyP4 (Fig. 3-1), was 
investigated by UV-Vis titration as control experiments. A significant increase and 
decrease of absorbance at 440 nm and 424 nm, respectively, was observed with the 
annealed Htelo-DNA (Fig. 3-6A), indicating that TMPyP4 bound to the G-quadruplex 
formed by Htelo-DNA. The binding stoichiometry of TMPyP4 with the telomeric 
G-quadruplex remains to be elucidated. Previous studies using UV-Vis and ITC showed 
stoichiometries of 1:1 (G-quadruplex:TMPyP4) and 1:2 for the strong and weak binding 
modes, respectively [44]. Thus, based on the assumption that the dominant 
stoichiometry is 1:1, the Ka value was estimated to be (3.6 ± 1.8) × 106 M-1 at 25°C 
according to the plot of absorbance of TMPyP4 at 424 nm vs. Htelo-DNA concentration 
(Fig. 3-6B). More importantly, DS-DNA and SS-DNA also decreased the peak at 424 
nm (Fig. 3-6B). These results indicate that, in contrast to anionic phthalocyanines, the 
selectivity of TMPyP4 to the G-quadruplex was extremely low as reported previously 
because of its cationic groups [29-32]. In addition, UV-Vis spectra of an anionic 
porphyrin, TS4 (Fig. 3-1), showed no change with the addition of Htelo-DNA, 
indicating that TS4 did not bind to the G-quadruplex [30]. These results support that a 
combination of large π-planar surface and peripheral anionic groups allows the anionic 
phthalocyanines to specifically bind to the G-quadruplex via stacking interaction. 
Fig. 3-5. Ni-APC binding to G-quadruplex with high selectivity. Plots of absorbance at 680 nm of 
Ni-APC as a function of Htelo-DNA, SS-DNA and DS-DNA in the absence of λ DNA, and 
Htelo-DNA in the presence of λ DNA at 20°C.  
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3.3.1.2. Effects of Excess dsDNA on Telomerase Inhibition Capacities 
The high selectivity of anionic phthalocyanines to the telomeric G-quadruplex should 
A                  B                       C 
Fig. 3-7. Results of the tsTRAP assay with various concentrations of Cu-APC (A) and TMPyP4 
(B). I.C. stands for the internal control. (C) The relative activity of telomerase with various 
concentrations (0, 0.1, 0.3, 1.0, 3.0 or 10 µM) of Cu-APC (red) and TMPyP4 (blue) in the absence 
of λ DNA. The relative activity value of 1 corresponds to the positive control, namely without 
Cu-APC or TMPyP4 (For details of the calculation of the relative activity, see the experimental 
section).  
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Fig. 3-6. TMPyP4 binding to G-quadruplex, dsDNA, and ssDNA, non-specifically. (A) UV-Vis 
spectra of TMPyP4 with Htelo-DNA (0, 0.05, 0.5, 2, 5, 8, or 10 µM) in a buffer containing 50 
mM MES-LiOH (pH 7.0) and 100 mM KCl at 25°C. (B) Plots of absorbance at 440 nm of 
TMPyP4 as a function of Htelo-DNA, SS-DNA, and DS-DNA.  
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inhibit telomerase activity even in the presence of excess dsDNA as found in cell nuclei. 
The inhibitory effects were studied in the absence or presence of λ DNA, mimicking 
genomic DNA, by a tsTRAP assay. In this improved TRAP assay, PCR was carried out 
with 50-fold diluted products of the telomerase reaction in order to inhibit ligands from 
interfering with PCR [39, 40]. In the absence of λ DNA, higher concentrations of 
A                                  B 
Fig. 3-9. The relative activity of telomerase with various concentrations of Ni-APC (A) and APC 
(B) in the absence or presence of λ DNA. The relative activity value of 1 corresponds to the 
positive control, namely without Ni-APC or APC.  
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Fig. 3-8. Results of the tsTRAP assay with various concentrations of Cu-APC (A) and TMPyP4 
(B) in the presence of λ DNA. I.C. stands for the internal control. (C) The relative activity of 
telomerase with various concentrations (0, 0.1, 0.3, 1.0, 3.0 or 10 µM) of Cu-APC (red) and 
TMPyP4 (blue) in the presence of λ DNA. The relative activity value of 1 corresponds to the 
positive control, namely without Cu-APC or TMPyP4.  
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Cu-APC reduced the tsTRAP products (Figs. 3-7A and 3-7C), and the IC 50 value (the 
concentration of ligand at 50% relative activity, see Materials and Methods) was 
estimated to be 1.2 µM. More importantly, Cu-APC inhibited telomerase activity even 
in the presence of λ DNA with the IC 50 value of 1.2 µM (Figs. 3-8A and 3-8C), which 
is identical to that in the absence of λ DNA. These results are in agreement with the 
spectroscopic studies and demonstrate that selective binding to the telomeric 
G-quadruplex enables Cu-APC to inhibit telomerase activity specifically even in the 
presence of excess dsDNA. Furthermore, Ni-APC and APC (Fig. 3-1) also inhibited 
telomerase reaction activity both in the absence and presence of λ DNA (Figs. 3-9A and 
3-9B). These results indicate that coordinating metal has little impact on telomerase 
inhibition by anionic phthalocyanines. In contrast to anionic phthalocyanines, both 
cationic porphyrins, TMPyP4 and Cu-TMPyP4, drastically lost their telomerase 
inhibition effects in the presence of λ DNA, while they reduced tsTRAP products in the 
absence of λ DNA (Figs. 3-7B, 3-7C, 3-8B and 3-8C). These results indicate that the 
non-specific binding of the cationic groups to λ DNA prevented these porphyrins from 
inhibiting telomerase activity. 
3.3.2. MC Effects on Functional Capacities of G-Quadruplex-Ligands 
3.3.2.1. MC Effects on Binding Capacities 
In order to study the effects of MC on the binding affinity between TMPyP4 and the 
A                                  B 
Fig. 3-10. (A) UV-Vis spectra of 1 µM TMPyP4 with 0-10 µM Htelo-DNA in a buffer containing 
50 mM MES-LiOH (pH 7.0), 100 mM KCl, and 40 wt% PEG 200 at 25°C. (B) Plots of 
normalized absorbance at 424 nm of 1 µM TMPyP4 as a function of Htelo-DNA at 0 (blue) and 
40 (red) wt% PEG 200 at 25°C. 
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G-quadruplex formed by Htelo-DNA, UV-Vis absorbance spectra of TMPyP4 with the 
annealed Htelo-DNA were measured in a buffer containing 100 mM KCl and 50 mM 
MES-LiOH (pH7.0) at 25°C; PEG 200 content was 0 or 40 wt% in each sample. The 
addition of Htelo-DNA decreased the absorbance of TMPyP4 at 424 nm both at 0 wt% 
and 40 wt% PEG 200 (Fig. 3-10A), indicating that TMPyP4 bound to the Htelo-DNA 
G-quadruplex under both conditions. According to the plot of the absorbance at 424 nm 
versus Htelo-DNA concentration (Fig. 3-10B), the Ka value at 40 wt% PEG 200 was 
calculated to be (4.3 ± 3.3) × 105 M-1, which was less by one order of magnitude than 
that at 0 wt% of PEG 200, (3.6 ± 1.8) × 106 M-1, at 25°C. These results show that MC 
reduced the binding affinity of TMPyP4 for the G-quadruplex, which is consistent with 
Tan’s report that the elevation of the stability of the G-quadruplex, 
5’-(GGGTTA)3GGG-3’, by TMPyP4 was decreased under MC conditions compared to 
the diluted condition [33]. 
It is known that TMPyP4 binds to G-quadruplexes via two kinds of binding modes, 
π-π stacking and electrostatic interactions. In order to determine which binding mode 
was inhibited by MC, PIPER (Fig. 2-11), another cationic G-quadruplex-ligand, which 
also binds to the G-quadruplex via π-π stacking and electrostatic interactions was 
further studied [36]. Unlike TMPyP4, the affinity of PIPER for the G-quadruplex 
decreased as pH increased from 6.0 to 8.0; this decrease in affinity was attributed to the 
Fig. 3-11. Comparison of Ka values of PIPER for the Htelo-DNA G-quadruplex in the absence 
and presence of PEG 200 at pH 5.6 and 6.8 at 25°C. Each value is the average of three repeated 
measurements. 
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decrease in net positive charges on PIPER [36]. Thus, the electrostatic interaction 
between PIPER and the G-quadruplex could be controlled via the pH of the solution. 
UV-Vis titration of PIPER with Htelo-DNA showed that, at 25°C, the Ka values for 0 or 
40 wt% PEG 200 at pH 5.6 were (1.2 ± 0.7) × 106 M-1 or (3.0 ± 0.5) × 105 M-1, 
respectively, and the Ka values for 0 or 40 wt% PEG 200 at pH6.8 were (7.2 ± 2.0)× 105 
M-1 or (4.2 ± 2.9) × 105 M-1, respectively (Fig. 3-11). As was the case for TMPyP4, the 
Ka values of PIPER for Htelo-DNA decreased with MC at both pHs. Notably, the Ka 
values for 40 wt% PEG 200 were 4.0 times (pH 5.6) and 1.7 times (pH 6.8) smaller than 
those for 0 wt% PEG 200. MC caused a larger decrease in the binding affinity between 
PIPER and Htelo-DNA at pH 5.6 more than it did at pH 6.8. The electrostatic attraction 
between PIPER and the G-quadruplex should have been enhanced at pH 5.6 relative to 
that at pH 6.8 due to the increase in net positive charges [36]. Therefore, these results 
further support the hypothesis that MC with PEG 200 inhibited the electrostatic 
attraction between cationic ligands and the G-quadruplex. 
Since it is conceivable that MC can inhibit electrostatic interactions between ligands 
and the G-quadruplex, it was attempted to further assess whether π-π stacking 
interactions can maintain their binding energy under MC conditions. Cu-APC should 
not engage in electrostatic interactions with G-quadruplexes because of their negative 
charges; however, it should engage in π-π stacking interactions with G-quadruplexes. 
Thus, in order to examine MC effects on π-π stacking interaction, the binding affinity 
between Cu-APC and the G-quadruplex formed by Htelo-DNA was investigated under 
MC conditions. UV-Vis spectra of Cu-APC were measured with the annealed 
Htelo-DNA at 0 wt% and at 40 wt% PEG 200 (Figs. 3-12A and 3-12B). Based on the 
plots of the absorbance at 690 nm versus Htelo-DNA concentration, the Ka values at 
25°C were determined to be (2.8 ± 1.2) × 104 M-1 and (3.4 ± 1.5) × 104 M-1 at 0 wt% 
and 40 wt% PEG 200, respectively (Fig. 3-12B). These results demonstrated that the 
binding affinity of Cu-APC for the G-quadruplex was not influenced by MC. In addition, 
the binding between Hemin (Fig. 3-1), another anionic ligand, and Htelo-DNA was also 
examined (Fig. 3-13). At 25°C, the Ka values at 0 wt% PEG 200 were almost the same 
as those at 40 wt% PEG 200 ((2.7 ± 1.1) × 105 M-1 and (3.2 ± 1.2) × 105 M-1 at 0 and 40 
wt% PEG 200, respectively). These results for Cu-APC and Hemin support the notion 
that anionic G-quadruplex-ligands can maintain their binding affinity for the 
G-quadruplex even under conditions of MC. Thus, it is possible to conclude that π-π 
stacking interactions are able to maintain binding between anionic ligands and the 
G-quadruplex under conditions of MC. The mechanism of the maintenance was further 
explored as described in 3.3.3. 
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3.3.2.2. MC Effects on Telomerase Inhibition Capacities 
Decrease in the binding affinity of TMPyP4 with the G-quadruplex should prevent 
TMPyP4 from inhibiting telomerase activity under MC conditions. To investigate this 
hypothesis, the tsTRAP assay with TMPyP4 was carried out under MC condition [39, 
40]. As expected, the IC50 value at 20 wt% PEG 200 was 14 ± 1.0 µM, which was 
obviously larger than that at 0 wt% PEG 200, 2.3 ± 1.1 µM (Figs. 3-14A and 3-14B). 
Fig. 3-13. Plots of normalized absorbance at 405 nm of 12.5 µM Hemin as a function of 
Htelo-DNA concentration in a buffer containing 50 mM MES-LiOH (pH 7.0) and 100 mM KCl at 
0 (blue) and 40 (red) wt% PEG 200. 
A                                  B 
Fig. 3-12. (A) UV-Vis spectra of 2.5 µM Cu-APC with 0-250 µM Htelo-DNA in a buffer 
containing 50 mM MES-LiOH (pH 7.0), 100 mM KCl, 40 wt% PEG 200 at 25°C. (B) Plots of 
normalized absorbance at 690 nm of 2.5 µM Cu-APC as a function of Htelo-DNA at 0 (blue) and 
40 (red) wt% PEG 200.  
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Fig. 3-14. (A) Results of the tsTRAP assay with various concentrations of TMPyP4 at 0 (left) and 
20 (right) wt% PEG 200. I.C. stands for the internal control. (B) The relative activity of 
telomerase as a function of TMPyP4 at 0 (blue) and 20 (red) wt% PEG 200. 
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These MC effects were consistent with reduced telomerase inhibitory effect of TMPyP4 
in the presence of PEG 200 in Tan’s report [33]. Taken together, the results of the 
binding and tsTRAP assays indicated that MC reduced TMPyP4-mediated telomerase 
inhibition by decreasing the binding affinity between TMPyP4 and the G-quadruplex. 
On the other hand, the lack of MC effects on the binding of Cu-APC or Hemin to the 
G-quadruplex indicates that inhibitory effects that these ligand have on telomerase can 
be maintained even under MC condition. The tsTRAP assays with Cu-APC at 0 or 20 
wt% PEG 200 revealed that the IC50 values at 0 and 20 wt% PEG 200 were 1.0 ± 0.2 
µM and 1.8 ± 0.8 µM (Figs. 3-15A and 3-15B). Similar to Cu-APC, the IC50 values of 
Hemin were also almost independent of PEG 200 concentration (38 ± 24 µM and 99 ± 
24 µM at 0 and 20 wt% PEG 200, respectively) (Figs. 3-15C and 3-15D). These results 
demonstrated for the first time that anionic G-quadruplex-ligands can inhibit telomerase 
activity under conditions of MC as efficiently as in the absence of MC. 
3.3.3. Behavior of Water Molecules upon Binding of G-Quadruplex-Ligands 
The UV-Vis titration assays showed that MC prevented cationic 
G-quadruplex-ligands, but not anionic G-quadruplex-ligands, from binding to the 
G-quadruplex. To date, the effects of osmotic pressure as it relates to the activity of 
water molecules altered by MC have been investigated mainly on various 
dsDNA-ligands including intercalators and groove binders [45-50]. MC reduced the 
affinities of the most ligands for dsDNA by decreasing water activity. Moreover, 0.25 to 
78 water molecules are taken up upon the binding of ligands to dsDNA (Table 3-1) 
[45-50]. Because a hydration reaction is unfavorable under conditions where the 
concentration and activity of water molecules is decreased, the reduction of ligand 
affinity should be attributed to the water molecules taken up upon binding. Therefore, 
the binding affinities of TMPyP4 or Cu-APC to the G-quadruplex at PEG 200 
concentrations between 0 and 40 wt% was further studied in order to examine how the 
activity of water molecules affected G-quadruplex-ligand binding (Figs. 3-16A and 
Fig. 3-15. (A) Results of the tsTRAP assay with various concentrations of Cu-APC at 0 (left) and 
20 (right) wt% PEG 200. I.C. stands for the internal control. (B) The relative activity of 
telomerase as a function of Cu-APC at 0 (blue) and 20 (red) wt% PEG 200. (C) Results of the 
tsTRAP assay with various concentrations of Hemin at 0 (left) and 20 (right) wt% PEG 200. I.C. 
stands for the internal control. (D) The relative activity of telomerase as a function of Hemin at 0 
(blue) and 20 (red) wt% PEG 200.  
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3-16B). It was found that the relationships between ln Ka (the observed equilibrium 
constant) for binding of TMPyP4 to the G-quadruplex and ln aw (the water activity) 
were linear and that they depended upon the concentration of PEG 200 (Fig. 3-17A), 
although MC induced a conformational change of the Htelo-DNA G-quadruplex. Based 
on the plots of ln Ka versus ln aw (Fig. 3-17A), approximately 32 ±1.7 water molecules 
were taken up upon binding of TMPyP4 to G-quadruplex. The numbers of ∆nw 
Table 3-1. The number of water molecules (∆nw) released upon the binding of ligand 
to DNA 
DNA sequence DNA structure Ligand Cosolute ∆n w Reference
Calf thymus  DNA dsDNA Ethidium Sucrose (Triethylene glycol,
Betaine) -0.25 45,46
Propidium Sucrose (Triethylene glycol,
Betaine) -6.4
Proflavine Sucrose (Triethylene glycol,
Betaine) -30
Daunomycin Sucrose (Triethylene glycol,
Betaine) -18
7-aminoactionomycin D Sucrose (Triethylene glycol,
Betaine) -32
d(CGCGCAATTGCGCG)2 dsDNA Hoechst 33258 Triethylene glycol -78 47
Acetamide -51
Betaine -51
Tetraethylene glycol -67
d(CGCGCAATTGCGCG)2 dsDNA DAPI Triethylene glycol (Actamide,
Betaine, -35 48
Netropsin Triethylene glycol (Actamide,
Betaine, -26
Pentamidine Triethylene glycol (Actamide,
Betaine, -34
Calf thymus  DNA dsDNA Daumocycin Sucrose (Triethylene glycol,
Betaine) -17.8 49
Adriamycin Sucrose (Triethylene glycol,
Betaine) -35.8
Calf thymus DNA dsDNA Hoechst 33258 Triethylene glycol -74 50
Sucrose -30
d(GGGTTA)3GGG G-quadruplex TMPyP4 Glycerol -30 33
dA(GGGTTA)3GGG G-quadruplex Berberine Low molecular weight cosolute -13 51
d(GGGTTA)3GGG G-quadruplex TMPyP4 EG -16 This thesis
PEG 200 -32
PEG 8000 -40
PIPER PEG 200 (pH 5.6) -30
PEG 200 (pH 6.8) -13
Cu-APC EG -5.5
PEG 200 7.0
PEG 8000 5.3
Hemin PEG 200 8.4
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evaluated in the present assay as well as previous reports are listed in Table 3-1. These 
results were in agreement with those from previous reports, which showed that more 
than 10 water molecules are acquired upon binding of cationic ligands to the 
G-quadruplex (Table 3-1) [33, 51]. More importantly, the plots of ln Ka for Cu-APC 
versus ln aw showed (Fig. 3-17A) that several water molecules (7.0 ± 8.5 water 
molecules) were released upon Cu-APC binding to the G-quadruplex (Table 3-1). 
Therefore, it was possible to conclude that MC with PEG 200 reduced binding affinity 
of TMPyP4 to the G-quadruplex because of the hydration that occurs with 
G-quadruplex/TMPyP4 complex formation, although acquisition of no water molecules 
Fig. 3-17. Plots of ln Ka versus ln aw for binding of TMPyP4 or Cu-APC with Htelo-DNA at 0 to 
40 wt% PEG 200 (A), 0 to 40 wt% EG (B), and 0 to 20 wt% PEG 8000 (C).  
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Fig. 3-16. Plots of normalized absorbance at 424 nm of 1 µM TMPyP4 (A) and at 690 nm of 2.5 
µM Cu-APC (B) as a function of Htelo-DNA concentration in a buffer containing 50 mM 
MES-LiOH (pH 7.0) and 100 mM KCl at 0-40 wt% PEG 200 at 25°C.  
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during G-quadruplex/Cu-APC complex formation allowed for the maintenance of the 
affinity under MC conditions. 
In order to further confirm the importance of water activity in the 
G-quadruplex/ligand complex formation, the effects of two other cosolutes such as EG 
and PEG 8000, which were different in size from PEG 200, were examined. Results 
from assays with 0~40 wt% EG (Figs. 3-18A and 3-18B for TMPyP4 and Cu-APC, 
respectively) showed that more water molecules were taken up upon formation of 
G-quadruplex/TMPyP4 complexes (16 ± 1.3 water molecules) than upon formation 
G-quadruplex/Cu-APC complexes (5.5 ± 1.4 water molecules) (Fig. 3-17B and Table 
3-1). Results from assays with PEG 8000 (Figs. 3-18C and 3-18D for TMPyP4 and 
Cu-APC, respectively) showed that a significant number of water molecules (40 ± 26 
Fig. 3-18. Plots of normalized absorbance at 424 nm of 1 µM TMPyP4 (A) and 690 nm of 2.5 µM 
Cu-APC (B) as a function of Htelo-DNA concentration in a buffer containing 50 mM MES-LiOH 
(pH 7.0) and 100 mM KCl at 0-40 wt% EG at 25°C, and plots of normalized absorbance at 424 
nm of 1 µM TMPyP4 (C) and 690 nm of 2.5 µM Cu-APC (D) as a function of Htelo-DNA 
concentration in a buffer containing 50 mM MES-LiOH (pH 7.0) and 100 mM KCl at 0-20 wt% 
PEG 8000 at 25°C.  
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water molecules) were taken up upon the G-quadruplex/TMPyP4 complex formation, 
despite the smaller number of water molecules (5.3 ± 7.1 water molecules) released 
upon the G-quadruplex/Cu-APC complex formation (Fig. 3-17C and Table 3-1). These 
results strongly supported the idea that anionic G-quadruplex-ligands are stronger 
telomerase inhibitor than cationic ligands under conditions of decreased water activity 
that were induced with various cosolutes. 
3.4. Discussion 
3.4.1 Uptake of Significant Numbers of Water Molecules upon Cationic 
G-Quadruplex-Ligands Binding to G-quadruplex 
The results of UV-Vis titration assays with cosolutes indicated that electrostatic 
attraction in the G-quadruplex/ligand complex required larger numbers of water 
molecules than pi-pi stacking interaction, and this requirement for water molecules 
should reduce more drastically the cationic ligands binding to the G-quadruplex and the 
consequent telomerase inhibition under conditions of decreased water activity compared 
to the anionic ligands (left panel in Fig. 3-19). Previous studies on dsDNA-ligands 
Fig. 3-19. Cationic ligands bind to G-quadruplex with uptake of many water molecules (left); in 
contrast, anionic ligands binding to G-quadruplex with uptake of very few water molecules 
(right).  
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showed that indirect contacts between ligands and dsDNA, including electrostatic 
interaction, required water molecules, and that proximal contacts displaced interfacial 
water molecules [47, 50, 52, 53]. For example, Hoechst 33258, which binds in the 
minor-groove with a cationic functional group at its terminal, is concave and closely 
interacts with the minor groove through hydrogen and van der Waals contacts [47, 54, 
55]. Displacement of interfacial water molecules between Hoechst 33258 and the minor 
groove was demonstrated by X-ray crystallography as well as in thermodynamic and 
molecular dynamic simulation studies [47, 55-57]. However, osmotic stress studies 
showed that the Hoechst 33258/dsDNA complex acquired several tens of water 
molecules [47, 50]. These results suggest that the cationic terminal group of Hoechst 
33258 binds to phosphate groups in minor groove of dsDNA through a network of water 
molecules [47]. Moreover, there have been other instances of water molecules bridging 
between other cationic ligands that bind in grooves of dsDNA [58, 59]. These findings 
demonstrate that water molecules are generally taken up upon formation of electrostatic 
interactions between the cationic ligands and dsDNA. In addition, NMR analysis 
showed that TMPyP4 is stacked over the top of G-quartet in a G-quadruplex from a 
MYC promoter and the cationic functional groups of TMPyP4 are in close contact with 
some phosphates of the G-quadruplex [60]. The results here for TMPyP4 and PIPER 
were consistent with those from the prior studies, and together these findings indicate 
that water molecules play a functional role in electrostatic interactions between DNA 
structures and cationic ligands by forming bridges between the DNA and the ligand. 
3.4.2. Release of Several Water Molecules upon Anionic G-Quadruplex-Ligands 
Binding to G-quadruplex 
In contrast to the cationic ligands, results of binding assays of Cu-APC to the 
G-quadruplex at various concentrations of PEG 200 showed that several water 
molecules were released when Cu-APC bound to the G-quadruplex (Fig. 3-17A). As 
shown in the case with Cu-APC, similar numbers of water molecules were released 
upon the G-quadruplex/Hemin complex formation (Fig. 3-20). These water behaviors 
were similar to that observed when ethidium bromide, a dsDNA-intercalator, binds to 
dsDNA. No water molecules were taken up upon formation of the ethidium 
bromide/dsDNA complex; however, binding of other dsDNA intercalators to dsDNA 
resulted in the acquisition of water molecules (Table 3-1) [45, 46]. These findings are 
attributable to the facts that ethidium bromide binds to dsDNA via pi-pi stacking 
interactions and that it has very few functional groups that can interact with the minor 
groove because of its small size. Similarly, the reason that there were almost no water 
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molecules taken up upon binding of the anionic ligands, Cu-APC and Hemin, to the 
G-quadruplex should be that binding mode of these ligands was mainly the pi-pi stacking 
interaction due to the anionic functional groups. Furthermore, previous structural 
studies of G-quadruplex/ligand complexes showed that G-quadruplex-ligands are 
usually stacked over the top G-quartet, which may also be an important factor for the 
water behavior upon pi-pi stacking interaction. In the absence of ligands, the top 
G-quartet is known to form a rigid stacking interaction with a loop, of which length is 
more than three bases [61]. The well-ordered loop structure accumulates functional 
groups that can be binding sites for water molecules [61]. The end stacking interaction 
of G-quadruplex-ligands should alter the well-ordered loop structure bounded by water 
molecules, which may result in release of water molecules. Thus, to the best of our 
knowledge, these results indicated for the first time that decreased water activity does 
not reduce the binding affinity of anionic ligands for G-quadruplex and that this 
maintenance of binding under MC conditions resulted in the maintenance of the 
telomerase inhibitory effect (right panel in Fig. 3-19). 
3.4.3. Other Factors Affecting Water Behavior upon G-Quadruplex/Ligands 
Formation 
The slopes of plots of ln Ka for TMPyP4 or Cu-APC versus ln aw depended on the 
cosolutes; these findings indicated that not only water activity, but also other solution 
factors, affected the binding affinities of these ligands (Fig. 3-18). Water molecules 
taken up or released upon the binding of TMPyP4 and Cu-APC, respectively, to the 
G-quadruplex tended to increase when cosolutes with larger weight molecule were 
Fig. 3-20. Plots of ln Ka versus ln aw for binding of Hemin with Htelo-DNA at 25°C. 
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added (Table 3-1). A previous study on the MC effect as caused by cosolutes with 
different molecular weights, specifically PEG 200 and Ficoll 70, showed that these 
cosolutes differed in their effects on the interaction between TMPyP4 and a telomeric 
G-quadruplex [62]. Thus, the molecular weight of a cosolute can have an impact on 
some properties of a solution, and this impact may be related to the change in the 
number of water molecules taken up or released upon binding. The viscosity increases 
progressively with increases in the molecular weight of PEG [63]. The addition of EG 
and PEG decreases the dielectric constant of the solution, and the higher the molecular 
weight of PEG the larger the reduction in the dielectric constant [63]. An increase in 
viscosity should reduce the affinity of TMPyP4 or Cu-APC for G-quadruplex, and a 
decrease in the dielectric constant should enhance or reduce the affinity of TMPyP4 or 
Cu-APC, respectively. However, the Ka value for TMPyP4 or Cu-APC tended to 
decrease or increase, respectively, with the increasing concentrations of the cosolutes. 
Thus, these two solution properties may not be the main cause for the observed 
tendency in the number of taken up or released water molecules. The order of the 
numbers of water molecules taken up or released upon the G-quadruplex-TMPyP4 or 
G-quadruplex/Cu-APC complex formation, respectively, was inversely related to the 
numbers of hydroxyl groups in the vicinal position in the cosolutes. Previous studies on 
the effect of MC on formation of G-quadruplex and dsDNA demonstrated that a 
cosolute with fewer hydroxyl groups in the vicinal position causes more water 
molecules to be released during formation of an antiparallel G-quadruplex or to be taken 
up during formation of a DNA duplex [23, 24]. This relationship is attributable to the 
fact that the solvation of DNA by cosolutes with more hydroxyl groups eliminates the 
uptake or release of water molecules because the cosolutes with more hydroxyl groups 
can bind to DNA molecules directly and may be released or taken up along with the 
uptake or release of water molecules during formation of multi-strand DNA structure 
[24]. Although clarification of the influences of solution properties on 
G-quadruplex/ligand complex formation requires further studies, the hydration or 
dehydration that occurs during formation of G-quadruplex/ligand complexes may also 
be affected by the hydroxyl groups on the cosolutes. 
3.5. Conclusions 
The telomeric G-quadruplex-binding and telomerase-inhibiting capacities of 
G-quadruplex-ligands were systematically examined under the diluted condition and the 
cell nuclei-mimicking condition where λ DNA or MC cosolutes such as EG, PEG 200, 
and PEG 8000 exist. Although cationic ligands such as TMPyP4 and Cu-TMPyP4 
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bound to the telomeric G-quadruplex under the diluted condition without λ DNA and 
MC cosolutes, the binding affinity was drastically reduced by addition of λ DNA. The 
reduction should be caused by electrostatic binding to λ DNA. MC also inhibited 
cationic ligands from binding to the G-quadruplex. Studies on water behavior indicated 
that the reduced binding affinity under MC conditions is caused by uptake of water 
molecules upon binding of their cationic functional groups to the G-quadruplex. In 
accordance with these results, λ DNA and PEG 200 also decreased the telomerase 
inhibitory effect of cationic ligands. More importantly, both λ DNA and MC did not 
affect the binding capacities and the subsequent telomerase inhibitory capacities of 
anionic ligands such as Cu-APC, Ni-APC, Hemin, and APC, because they did not 
interact with dsDNA and acquire water molecules upon binding to G-quadruplex. These 
results indicate that anionic ligands show specific antiproliferative effect on tumor cells 
over normal cells via efficient telomerase inhibition even in cell nuclei. 
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4. Development of an Assay for Telomerase Activity without False Negative Results 
4.1. Introduction 
In most human cancer cells, telomerase is highly-activated and plays a key role of the 
immortal cell proliferation, although the activity has not been detected in various 
normal somatic cells [1, 2]. Thus, telomerase has been suggested as a promising marker 
for cancer diagnosis. Several studies showed the association between the telomerase 
activity and a number of prognostic and clinopathological features in colorectal cancer 
[3-9]. For the diagnosis with telomerase activity as a marker, the assay for telomerase 
activity, which is precise and sensitive, is required. 
A conventional assay for telomerase activity is TRAP assay (Fig. 2-13) [1]. In the 
assay, a telomerase reaction is carried out using an artificial oligodeoxynucleotide called 
TS primer, which serves as a primer for telomerase similarly to telomeric DNA. 
Following the telomerase reaction, the reaction products are amplified by PCR using TS 
primer as a forward primer. Finally, the amplification products are analyzed 
electrophoretically. Although TRAP assay is a powerful tool due to its high sensitivity, it 
is still difficult to apply to practical cancer diagnostics. This is because the assay is 
susceptible to polymerase inhibition by clinical extract, which leads to the false negative 
result [10]. Thus, many research groups have developed other telomerase assays based 
on various sensors or methodologies, such as optical fiber [11], magnetic resonance 
reader [12], magneto-mechanical detector [13], ISFET [14], electrochemical method 
[15], photonic microring device [16], and surface plasmon resonance method [14, 17]. 
In general, such assays do not utilize any signal amplification processes like PCR and 
were therefore less sensitive than TRAP assays. Other groups proposed telomerase 
assays with novel signal amplification processes involving enzymes [18-21], 
DNAzymes [22-24], and nanoparticles [25-28], instead of PCR. Although some of these 
assays with novel amplification reactions detected telomerase activity with high 
sensitivity, the enzymes used for catalysis-based amplification may be inhibited by 
components in clinical samples. Thus, a novel sensitive telomerase assay that can avoid 
such false negative results has been required. Here, to meet the requirement, a 
telomerase assay based on A-PCR [29, 30] on MBs and subsequent application of CPT 
[31] involving a Probe RNA and RNase H is reported. 
4.2. Materials and Methods 
4.2.1. Materials and Reagents 
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All deoxyribo-oligonucleotides were HPLC purification-grade 
deoxyribo-oligonucleotides, and were purchased from Tsukuba Oligo Service Co., Ltd., 
or were provided in a TRAPEZE telomerase detection kit from EMD Millipore 
Corporation (Billerica, MA, USA). λ DNA was purchased from Takara Bio Inc. All 
ribo-oligonucleotides were HPLC purification-grade ribo-oligonucleotides, and were 
purchased from Tsukuba Oligo Service Co., Ltd. HeLa and NHDF cells were provided 
in TRAPEZE telomerase detection kits and purchased from Toyobo Co., Ltd. (Osaka, 
Japan), respectively. RNase H was purchased from Takara Bio Inc. (Shiga, Japan). The 
polymerase used for PCR was the TaKaRa LA Taq HS that was provided the in TaKaRa 
LA Taq Hot Start Version from Takara Bio Inc. Streptavidin-coated MBs were 
Dynabeads M-280 purchased from Life Technologies Corporation (Carlsbad, CA, USA). 
Dynabeads M-280 were washed three times in a buffer containing 10 mM Tris-HCl (pH 
7.5) and 2 M KCl before use. Cu-APC was purchased from Sigma-Aldrich corporation. 
4.2.2. Preparation of Cell Lysate 
A pellet of 106 cells was suspended in 200 µL of cold 
3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) lysis buffer 
provided in the TRAPEZE telomerase detection kit. The cell lysate solution was 
dispensed into small volume aliquots and stored at -80°C. Each cell lysate aliquot was 
diluted in cold CHAPS lysis buffer as appropriate before use. 
4.2.3. CPT for Model Sequence of Telomerase Products ( MSTP) Detection 
CPT for MSTP detection was performed to identify a probe RNA suitable for the 
A-PCR/CPT assay. Each type of probe RNA (100 nM) was annealed separately with 
each of several concentrations of MSTP in a buffer containing 50 mM Tris-HCl (pH8) 
and 4 mM MgCl2. Each reaction solution was incubated with 0.1 U/µL RNase H at 
30°C for 0.5 h, and then mixed with 50 mM Na2EDTA to terminate the reaction; a 
fluorescence spectral scanning reader (Varioskan flash; Thermo Fisher Scientific Inc., 
Waltham, MA, USA) with excitation set to 482 nm was then used to measure the 
fluorescence intensity of the solution at 500-550 nm and 25°C. 
4.2.4. MSTP Digestion Assay 
To assess DNase activity in the HeLa cells lysates, HeLa cells lysate was incubated 
with MSTP, and subject to a digestion assay. MSTP (100 nM) was incubated at 37°C for 
60 min with HeLa cell lysate solution containing 0 or 125 cells/µL in a buffer of 20 mM 
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Tris-HCl (pH 8.0) and 4 mM MgCl2 or 10 mM Na2EDTA. Each sample was then 
analyzed via gel electrophoresis on a 10% denaturing urea polyacrylamide gel in 
Tris-borate-EDTA buffer (pH 8.5) at 400 V. Each gel was stained with SYBR Gold 
nucleic acid gel stain (Life Technologies Corporation) and imaged using a fluorescence 
image analyzer (FLA-5100; Fuji photo film Co., Ltd., Tokyo, Japan). 
4.2.5. Telomerase Reaction 
Each telomerase reaction solution (10 µL) contained 1×TRAP buffer (TRAPEZE 
telomerase detection kit), 1×dNTPs (TRAPEZE telomerase detection kit), non-modified 
TS primer (TRAPEZE telomerase detection kit), HeLa cells lysate, and one of several 
concentrations of λ DNA; each mixture was incubated at 37°C for 60 min, heated at 
95°C for 10 min, and cooled at 4°C. To generate telomerase reaction products that could 
be immobilized on MBs, 1 µM biotinylated TS primer was used instead of the 
non-modified TS primer. 
4.2.6. Immobilization of Telomerase Reaction Products on MBs 
A vortex was used to mix 10 µL of telomerase reaction product, which was generated 
with 1 µM biotinylated TS primer, with prewashed MBs (Dynabeads M-280) that were 
in 10 µL of a buffer containing 10 mM Tris-HCl (pH 7.5) and 2 M KCl; these 20 µL 
were mixed at 25°C for 30 min. The treated MBs were then subject to three sequential 
washes, each with 20 µL of buffer containing 10 mM Tris-HCl (pH 7.5) and 1 M NaCl, 
and one last wash with 20 µL of water.  
4.2.7. A-PCR Amplification of Telomerase Reaction Products 
A-PCR amplification of telomerase reaction products was carried out in a solution 
containing telomerase reaction products (telomerase reaction solutions or MBs with 
telomerase reaction products), 1×LA PCR Buffer II (Mg2+ plus), 1×dNTPs, any one of 
several concentrations of TS primer, 1 µM CX-ext primer, and 0.05 U/µL TaKaRa LA 
Taq HS, for 30 cycles with each cycle comprising denaturation at 95°C for 30 s, 
annealing at 59°C for 30 s, and extension at 72°C for 30 s. After A-PCR amplification, 
the reaction mixtures were cooled and stored at 4°C. 
4.2.8. CPT for Detection of A-PCR Products 
A-PCR products were detected by CPT. Each CPT reaction mixture (100 µL) 
contained A-PCR reaction mixture with products (10 µL), 100 nM probe RNA 2, 50 
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mM Tris-HCl (pH8), and 4 mM MgCl2; each mixture was incubated with 0.1 U/µL 
RNase H at 37°C for 20 min. Na2EDTA (50 mM) was added to terminate the reaction; a 
fluorescence spectral scanning reader (Varioskan flash) set with excitation at 482 nm 
was used to measure the fluorescence intensity of each solution at 500-550 nm and 
25°C. 
4.2.9. Normal PCR Amplification of Telomerase Reaction Products 
PCR amplification of telomerase reaction products was carried out in a reaction 
mixtures that each contained telomerase reaction products, 1×LA PCR Buffer II (Mg2+ 
plus) (Takara Bio Inc.), 1×dNTPs (TRAPEZE telomerase detection kit), TS primer 
(TRAPEZE telomerase detection kit), Primer Mixture solution (TRAPEZE telomerase 
detection kit), and 0.05 U/µL TaKaRa LA Taq HS (Takara Bio Inc.); amplification 
occurred over 30 cycles, each comprising denaturation at 95°C for 30 s, annealing at 
59°C for 30 s, and extension at 72°C for 30 s. After PCR amplification, each reaction 
mixture was cooled and stored at 4°C. The PCR products were analyzed by native gel 
electrophoresis on a 10% nondenaturing polyacrylamide gel in Tris-borate-EDTA buffer 
(pH 8.5) at 400 V. The gels were stained with GelStar nucleic acid gel stain and imaged 
using a fluorescent image analyzer (FLA-5100). 
4.2.10. One-Step TRAP Assay (Conventional TRAP Assay) 
Each one-step TRAP assay was carried out in a solution containing 1×TRAP buffer 
(TRAPEZE telomerase detection kit), 1×dNTPs (TRAPEZE telomerase detection kit), 
non-modified 1 µM TS primer, Primer Mixture solution (TRAPEZE telomerase 
detection kit), 0.05 U/µL TaKaRa LA Taq HS (Takara Bio Inc.), and HeLa cells lysate 
as follows: telomerase reaction for one cycle with incubation at 37°C for 30 min, and 
PCR for 30 cycles with denaturation at 95°C for 30 s, annealing at 59°C for 30 s, and 
extension at 72°C for 30 s; after each complete series of cycles, the solution was cooled 
at 4°C. The one-step TRAP products were analyzed by native gel electrophoresis on a 
10% nondenaturing polyacrylamide gel in Tris-borate-EDTA buffer (pH 8.5) at 400 V. 
The gels were stained with GelStar nucleic acid gel stain and imaged using a fluorescent 
image analyzer (FLA-5100). 
4.3. Results and Discussion 
4.3.1. Detection Principle 
Figure 4-1 depicts the principle of the telomerase assay described here. In principle, 
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Fig. 4-1. Strategy for the telomerase assay based on A-PCR on MBs and CPT: (i) telomerase in 
crude clinical extract elongates the telomeric DNA sequence from biotinylated TS primer, (ii) 
telomerase reaction products are immobilized on MBs via interaction between biotin and 
streptavidin, (iii) MBs coated with the telomerase products are washed to remove PCR inhibitors, 
(iv) the G-rich sequences of the telomerase products are preferentially amplified via A-PCR, and 
(v) amplified G-rich sequences are detected by CPT. 
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the assay includes the following steps: (i) telomerase elongates telomeric DNA 
sequence via a biotinylated TS primer (Table 4-1), which serves as a substrate for 
telomerase elongation, (ii) the biotin-labelled telomerase reaction products are 
immobilized on streptavidin-coated MBs via interaction between biotin and streptavidin, 
(iii) MBs coated with telomerase products are washed to remove sample contaminants 
including PCR inhibitors, (iv) the G-rich sequences of the telomerase products are 
preferentially amplified by A-PCR, and (v) amplified G-rich sequences are then 
detected via CPT. In CPT, a probe RNA with a fluorophore (fluorescein isothiocyanate; 
FITC) and a quencher (4-(dimethylaminoazo)benzene-4-carboxylic acid; Dabcyl) at the 
5’ end and 3’ end, respectively, hybridizes with the G-rich sequences. The hybridized 
probe RNA is hydrolyzed by RNase H, which recognizes RNA/DNA duplex and 
selectively hydrolyzes RNA in heteroduplexes. Before hydrolysis, fluorescence from 
FITC is quenched by fluorescence resonance energy transfer (FRET) due to proximity 
between FITC and Dabcyl. However, the hydrolysis of the probe RNA separates FITC 
from Dabcyl, which results in enhancement of the FITC fluorescence. Additionally, 
each reaction, including the hybridization of the probe RNA with the telomerase 
reaction products and the hydrolysis of the hybridized probe RNA by RNase H, occurs 
iteratively, which leads to a catalytic amplification of FITC signal. Importantly, in 
principle, the false negative results caused by PCR inhibitors should be completely 
avoided, and the combined application of A-PCR and CPT should lead to highly 
sensitive and selective detection of telomerase activity. 
4.3.2 Design of the Probe RNA 
The sequence and design of the probe RNA used for CPT is responsible for the 
sensitivity of this assay. Reducing the length of the probe should show lower 
background signals because FITC should be in closer proximity to Dabcyl; however, 
affinity between the probe and telomerase products should be lower with shorter probes. 
Conversely, longer probes should exhibit higher affinity for telomerase products and 
higher background signal. To optimize the probe RNA, four probes with FITC and 
Dabcyl at the 5’ end and 3’ end, respectively, were designed; the probes differed from 
one another in length and in sequence (Table 4-1). 
First, the RNase H reaction was carried out separately for each probe with 100 nM of 
probe in the absence or the presence of 100 nM MSTP (Table 4-1) at 37 °C for 30 min. 
For probe 1, an obvious peak of fluorescence with a maximum intensity around 520 nm 
was observed in the presence of both RNase H and MSTP (Fig. 4-2A). In contrast, in 
the absence of MSTP, the peak at 520 nm was clearly smaller, and the fluorescence at 
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Table 4-1. RNA oligonucleotides used in this study 
a
 Probes are FRET-modified complementary RNAs to telomere sequence. b MSTP is a model 
sequence of a telomerase product. c TS primer is a substrate DNA for telomerase and a forward 
primer for PCR amplification of telomerase reaction products. d Biotinylated TS primer is a TS 
primer with a 5’ biotin moiety for immobilization on streptavidin-coated magnetic beads. e CX-ext 
is a reverse primer for PCR amplification of telomerase reaction products. 
Name Sequence Modification
Probe 1 a 5'-CCCUAA-3' 5'-FITC/3'-Dabcyl
Probe 2 a 5'-CCCUAACCC-3' 5'-FITC/3'-Dabcyl
Probe 3 a 5'-CUAACCCUAAC-3' 5'-FITC/3'-Dabcyl
Probe 4 a 5'-CCCUAACCCUAACCC-3' 5'-FITC/3'-Dabcyl
MSTP b 5'-(GGGTTA)16-3' none
TS primer c 5'-AATCCGTCGAGCAGAGTT-3' none
Biotinylated 
TS primer d
5'-AATCCGTCGAGCAGAGTT-3' 5'-biotinylation
CX-ext e 5'-GTGCCCTTACCCTTACCCTTACCCTAA-3' none
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520 nm was about an eighteenth part of that in the presence of both RNase H and MSTP 
(Fig. 4-2A). Additionally, the fluorescence in the absence of RNase H was almost 
identical to that in the absence of MSTP. These results indicate that probe 1 hybridized 
with MSTP and that as expected RNase H hydrolyzed only the hybridized probe. Each 
other probe (probes 2, 3, and 4) also exhibited more fluorescence in the presence of 
MSTP than that in the absence of MSTP (Fig. 4-2B). However, the signal/background 
ratio values of probe 3 (2.6) and probe 4 (2.5) were less than those of probe 1 (11.5) and 
probe 2 (5.7). This difference occurred because, in the absence of MSTP, longer probes 
(probes 3 and 4) resulted in higher background fluorescence than did shorter probes 
(probes 1 and 2, Fig. 4-2B). The sensitivities of probes 1 and 2 were further investigated 
by carrying out the RNase H reaction with different concentrations (0-400 pM) of 
MSTP. The fluorescence at 520 nm of probe 1 decreased gradually as the concentration 
of MSTP decreased (Fig. 4-2C). However, the fluorescence from probe 2 with 
concentrations of MSTP between 80-400 pM were similar to each other and higher than 
those from probe 1; the fluorescence from probe 2 did decrease with decreases in MSTP 
concentration from 0-60 pM MSTP (Fig. 4-2C). Furthermore, a linear relationship 
between MSTP concentration and probe 2 fluorescence was found; the correlation 
equation for this relationship was probe 2 fluorescence at 520 nm = 6.01 + 1.31 × 
(MSTP concentration (pM)) (R2 = 0.9986) in the range of 0-10 pM (inset in Fig. 4-2C). 
Since a probability of that the fluorescence of the blank sample is larger than the 3.3 
times of its standard deviation (δ) is too low (0.05%) according to a standard normal 
distribution, the reliable detection limit with probe 2 was calculated to be 0.99 pM using 
the following equation (1): 
DL = 3.3 δ / S                                                         (1) 
where DL is the detection limit; δ is the standard deviation of the blank sample; and S is 
the slope of the correlation equation obtained by the linear relationship. The reaction 
volume was 100 µL; therefore, CPT with probe 2 should be detected MSTP at 
concentrations as low as 0.1 fmol. This concentration is two orders of magnitude lower 
Fig. 4-2. (A) Fluorescence spectra with probe 1 in the absence of 0.1 U/µL RNase H (green) or 
100 nM MSTP (blue), or presence of both (red). (B) Fluorescence at 520 nm with probes 1-4 in 
the absence or presence of 100 nM MSTP. Each value is the average calculated from the three 
replicate data sets and each error bar represents the standard deviation. (C) Plots of fluorescence 
at 520 nm with probe 1 or probe 2 vs. MSTP concentration. Each data point is the average 
calculated from the three replicate data sets and each error bar represents the standard deviation. 
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than that detectable with conventional gel electrophoresis analysis, 10 fmol (Fig. 4-3). 
These results showed that probe 2 is suitable for CPT and detection of telomerase 
reaction products. 
4.3.3. Inhibition of Degradation of Telomerase Reaction Products by Decoy DNA 
Cell lysate used without any prior purification contains various intracellular 
biomolecules, including DNase, that can degrade the products of telomerase reactions. 
Therefore, contaminants such as DNase can lead to false negative results from 
telomerase assays. To confirm that such problems occur, MSTP with or without HeLa 
cells lysate was kept in a buffer containing 50 mM MES-LiOH (pH 7.0) and 4 mM 
MgCl2 at 37°C for 60 min, and the degradation of MSTP was analyzed via gel 
electrophoresis. In the absence of HeLa cell lysate, a band corresponding to MSTP was 
observed (Fig. 4-4A); however, addition of HeLa cells lysate reduced the MSTP band. 
Moreover, when EDTA was used instead of Mg2+, addition of HeLa cells lysate did not 
reduce MSTP band (Fig. 4-4A). Since DNase requires divalent cations to activate the 
enzyme [32], these results indicated that DNase in cell lysate can degrade telomerase 
reaction products. To prevent such degradation, it was reasoned that addition of excess 
decoy DNA could prevent DNase from degrading the telomerase reaction products 
because the decoy DNA should serve as a competitive substrate for DNase. This 
assumption was confirmed by performing telomerase reaction with HeLa cells lysate in 
the absence or presence of various concentrations of λ DNA as the decoy DNA. The 
telomerase reaction mixtures were diluted 50-fold to reduce the influence of the decoy λ 
DNA on subsequent PCR; the telomerase reaction products were then amplified via 
PCR. PCR products were monitored via gel electrophoresis (Fig. 4-4B). In the absence 
Fig. 4-3. (A) Electrophoresis results of five different amounts of MSTP. (B) Relationship between 
band intensity of and amount of MSTP.  
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of λ DNA, long telomerase products were not abundant (Fig. 4-4B), indicating that 
DNase in HeLa cells lysate degraded the telomerase reaction products. However, long 
telomerase products were observed telomerase reactions containing λDNA, and the 
abundance of long products increase with increasing concentrations of λ DNA (Fig. 
4-4B). These results indicate that λ DNA efficiently inhibited DNase from degrading the 
telomerase reaction products by serving as a competitive substrate for DNase. Thus, 
addition of excess decoy DNA is a useful, easy, and cost-effective method for avoiding 
false negative results caused by DNase. 
4.3.4. Optimization of Primers Concentrations for A-PCR 
In the present assay, CPT with probe RNA and RNase H is used to achieve high 
sensitivity. A target DNA for CPT should be ssDNA, which can binds to probe RNA. 
Not normal PCR but A-PCR is appropriate for generating the target DNA, because the 
predominant product of A-PCR is ssDNA extended from a primer that is present in 
much higher concentrations than its partner primer [29, 30]. However, extremely 
different concentrations between the forward primer and the reverse primer can generate 
undesired artifact products. Thus, to optimize the concentration ratio of forward/reverse 
primers, telomerase reaction products in the absence or presence of 200 HeLa cells 
lysate were amplified by A-PCR with 1 µM to 50 µM TS primer and 1 µM CX-ext 
primer [33, 34] (Table 4-1) as the forward and reverse primers, respectively. The CX-ext 
primer (5'-GTGCCCTTACCCTTACCCTTACCCTAA-3') is complementary to four 
telomere repeats but contains a single base mismatch at the same position in each of 
Fig. 4-4. (A) Electrophoresis of MSTP-based telomerase reaction products in the absence or 
presence of HeLa cells lysates, Mg2+, and EDTA. (B) Electrophoresis of PCR-amplified 
telomerase reaction products synthesized in the presence of various concentrations of λ DNA. 
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three of the telomere repeats, and has three additional non-complementary nucleotides 
at its 5’ end [33, 34]. Therefore, the CX-ext primer functions as a reverse primer that 
reduces PCR-associated artifacts [33, 34]. CPT with probe 2 was used to detect the 
products amplified via A-PCR. In the absence of HeLa cell lysate, the fluorescence from 
probe 2 at 520 nm was identical to the fluorescence from probe 2 without MSTP 
(Compare the intensity from probe 2 without MSTP in Fig. 4-2 (B) and the intensity 
from probe 2 without HeLa cell lysate shown in Fig. 4-5). In addition, the fluorescence 
without HeLa cell lysate did not depend on the concentration of TS primer (Fig. 4-5). 
These results indicate that even highly concentrated TS primer did not generate any 
artifacts when paired with CX-ext primer, even though highly concentrated primers 
often cause PCR-associated artifacts. On the contrary, in the presence of HeLa cells 
lysate, the fluorescence from probe 2 with each concentration of TS primer was higher 
than that in the absence of HeLa cells lysate (Fig. 4-5). In addition, increases in the 
primer concentration up to 10 µM TS primer enhanced the fluorescence at 520 nm, and 
the fluorescence with 50 µM TS primer was almost the same as that with 10 µM TS 
primer. These results indicated that the amount of ssDNA that comprised telomere 
repeats increased as the concentration of TS primer increased up to 10 µM. Thus, 10 µM 
TS primer and 1 µM CX-ext primer were used in each subsequent assay. 
4.3.5. Detection of Telomerase Activity in Cells Lysate 
Based on the results described above, telomerase activity in HeLa cells lysate could 
Fig. 4-5. Fluorescence at 520 nm of probe 2 resulting from CPT with telomerase reaction 
products amplified via A-PCR using five different concentrations of TS primer. Each value is the 
average calculated from the three replicate data sets and each error bar represents the standard 
deviation.  
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be detected as follows: (i) Telomerase reaction carried out in the presence of λ DNA at 
37°C for 60 min. (ii) Telomerase reaction products immobilized on MBs at 25°C for 30 
min, and then washed with clean buffer. (iii) Telomerase reaction products on MBs 
amplified over 30 cycles of A-PCR with 10 µM TS primer and 1 µM CX-ext primer. 
(iv) A-PCR products detected by CPT with probe 2. These procedures were carried out 
with various numbers of HeLa cells (Fig. 4-6A). The fluorescence at 520 nm increased 
as a function of the number of HeLa cells (red square in Fig. 4-6B). A linear relationship 
between fluorescence intensity and HeLa cell number was also found; the correlation 
equation was fluorescence intensity = 5.71 + 0.022 × (number of HeLa cell) (R2 = 
Fig. 4-6. (A) Fluorescence spectra results from the A-PCR/CPT assays run with lysate with 
various concentrations of HeLa cells. (B, C) Plots of fluorescence intensity at 520 nm vs. the 
number of cells (red square: HeLa cells, blue diamond: NHDF cells, green square: HeLa cells in 
the presence of 5000 NHDF cells). Each data point for HeLa cells (red square) and NHDF cells 
(blue diamond) is the average calculated from the three replicate data sets, and each error bar 
represents the standard deviation.  
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0.984) within the range of 0-100 cells (red square in Fig. 4-6C). Based on this linear 
relationship, the limit of detection was calculated to be 50 cells using the above 
equation (1). These results indicate that the difference between the signal from 50 HeLa 
cells and that from no HeLa cells was statistically significant and the sensitivity of the 
present assay is higher than that of the common TRAP assay [35, 36]. In contrast, 100, 
1000, 5000, or 10000 NHDF cells, which have no telomerase activity, caused no 
fluorescence when used in our assay ((the fluorescent intensity with NHDF cells) - (the 
fluorescence intensity with no cells) < 0.01) (blue diamond in Figs. 4-6B and 4-6C). 
These results demonstrate that the fluorescence intensity depends on the telomerase 
activity. In addition, the fluorescence intensity when probing samples from 100–10000 
NHDF cells was almost the same as that when probing samples lacking cells, although 
RNA is very unstable especially in clinical samples. This lack of background probably 
resulted because the probe RNA was added into each CPT reaction mixture after most 
components of the cell extracts were separated from the telomerase reaction products. 
Thus, the probe RNA was not degraded by irrelevant components of the cell extracts, 
thereby avoiding false-positive results. These results indicate that this assay should be 
useful for detecting cancer cells with high sensitivity and specificity. Importantly, it was 
also found that, due to the high sensitivity, the fluorescence corresponding to the 
number of HeLa cells in the presence of 5000 NHDF cells (green square in Fig. 4-6B) 
was identical to that in the absence of NHDF cells. These results indicate that the assay 
allows the accurate detection of cancer cells even in the presence of a large excess of 
normal cells. Therefore, the assay should be practical for the detection of cancer cells in 
clinical samples. 
4.3.6. Eliminating False Negative Results Caused by PCR Inhibitors 
PCR inhibitors that exist in cells quantitatively reduce PCR amplification. The 
previous study showed that bile salt, heparin, and hemoglobin inhibited PCR at ≤ 1 
mg/mL, ≤ 1 IU/mL, and ≤ 1 mg/mL order or less, respectively [37]. The washing 
process on MBs in the present assay should eliminate the false negative results caused 
by such inhibitors. Therefore, effects of these PCR inhibitors—bile salt (1 mg/mL), 
heparin (2 IU/mL), and hemoglobin (1 mg/mL)—on the common one-step TRAP assay 
and our A-PCR/CPT assay were investigated; both assays were runs with HeLa cells 
lysate. In the one-step TRAP assay, all reagents for telomerase reaction and PCR, and 
the PCR inhibitors are included together in the reaction solution during the telomerase 
reaction and the PCR. The gel resulting from the one-step TRAP assay showed that 
ladder-like bands corresponding to the TRAP assay products and an internal control 
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band corresponding to PCR products from a 36-bp template were evident in the absence 
of PCR inhibitors (lane 1 in Fig. 4-7A). However, each inhibitor drastically reduced the 
amount of TRAP assay product and the internal control PCR products (lanes 2-4 in Fig. 
4-7A). These results indicate that a reduction of TRAP assay products was caused, at 
least in part, by PCR inhibitors. In contract, the fluorescence intensity results from the 
A-PCR/CPT assay showed that the fluorescence at 520 nm was similar regardless of the 
presence or absence of bile salt, hemoglobin, or heparin, and their fluorescence was 
significantly larger than that from the negative control without HeLa cells (p value 
<0.05) (Fig. 4-7B). These results indicate that the A-PCR/CPT assay, unlike the 
common one-step TRAP assay, can detect telomerase activity and simultaneously avoid 
the false negative results caused by PCR inhibitors including bile salt, heparin, and 
hemoglobin. Thus, the present assay should detect cancer cells with more accurately 
than the common one-step TRAP assay in the presence of PCR inhibitors. 
4.3.7. Comparison with Other Telomerase Assays 
Among a lot of telomerase assays developed so far, some have a washing procedure, 
in which telomerase reaction products immobilized on a solid phase such as a substrate 
and a particle are washed (Table 4-2) [13-17, 19, 20, 26-28, 38]. Their detection should 
Fig. 4-7. (A) Electrophoresis results from the one-step TRAP assay in the absence or presence of 
individual PCR inhibitors. (B) Fluorescence intensity results from the A-PCR/CPT assay with or 
without individual PCR inhibitors. Each value is the average calculated from the five replicate 
data sets and each error bar represents the standard deviation. * p <0.05.  
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not be affected by clinical samples due to the washing procedure. Thus, like the present 
assay, these assays can also be suitable for clinical application. Especially, the assays 
utilizing detection principles of Ag stain on Au nanoparticle (AuNP) with telomerase 
product on a chip [26] and [Ru(NH3)6]3+ bound to DNA on AuNP, which binds to 
telomerase product [28], showed a higher sensitivity of cancer cells (10 HeLa cells for 
both assays) than the present assay (50 HeLa cells) (Table 4-2). However, they take a 
long time (7 h and 4.5 h, respectively) (Table 4-2). In contrast, magneto-mechanical 
analysis of MB with telomerase reaction products takes a relatively short time (30 min), 
but its detection limit is 100 HeLa cells [13], which twice as many as that of the present 
assay (Table 4-2). Although SPR analysis of telomerase reaction also achieved a rapid 
detection, it can not be compared with the present assay because of different target 
Table 4-2. Comparison of telomerase assays with a washing process. 
a
 Detection limit of numbers of cancer cells (293T) is not shown in ref. 14. b Good correlation 
between electrochemical signal and numbers of cancer cells (HeLa cells) were observed in the 
range of 80-280 cancer cells. c Detection time does not include manual procedures. 
ISFET: ion-sensitive field-effect transmitter, SPR: surface plasmon resonance, ELISA: 
enzyme-linked immunosolbent assay, QCM: quartz crystal microbalance, BCIP: 
5-bromo-4-chloro-3-indolyl phosphate, AuNP: Au nanoparticle, ECL: electrochemiluminescence,  
Principle Cell Detection limit (cells) Detection time c Ref.
Magneto-mechanical detection of MB with
telomerase products HeLa 100 > 30 min 13
Telomerase reaction analysis by ISFET 293T 65±10 cells/µL a 1 h 14
SPR analysis of telomerase reaction 293T 18±3 cells/µL a 1 h 14
Electrochemical detection using ferrocene-
based telomeric G-quadruplex-ligand HeLa 80-280 
b 1 h 15 min 15
Detection of resonance wavelength shift
caused by telomerase reaction
J-82
HT-1376
100 cells in buffer
1000 cells in urine 1 h 30 min 16
SPR analysis of telomerase reaction T47-D 100 cancer cells
in 100000 normal cells 10 min 17
ELISA for telomerase products 293T 37500 > Over night 19
QCM analysis of BCIP precipitation
catalyzed by alkaline phosphatase, which is
linked to telomerase products
HeLa 1000 11 h 20
Detection of Ag stain on AuNP with
telomerase products
HeLa 10 7 h 26
Detection of ECL (Ru(bpy)32+) modified
probe DNA on AuNP, which binds to
HeLa 500 2 h 30 min 27
Detection of ECL ligand ([Ru(NH3)6]3+)
bound to DNA on AuNP, which binds to
HeLa 10 4 h 30 min 28
Luminescence analysis of luminol oxidation
by G-quadruplex DNAzyme of probe DNA HeLa 1000 17 h 38
Combination of A-PCR of telomerase
products on MB and CPT HeLa 50 (5 cells/µL)
2 h 50 min
(Telomerase reaction: 30 min,
PCR: 1 h 30 min, CPT: 20 min)
This thesis
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cancer cells [17] (Table 4-2). Furthermore, the present assay should enable a short 
detection because it uses PCR. Previously, PCR was cumbersome and took long hours. 
However, current improvement of DNA polymerases and development of lab-on-a-chip 
(LoC) technology for PCR allows DNA amplification in about 10 minutes or less 
[39-41]. Thus, the present assay with LoC technology should enable the detection of 
cancer cells in 1.5 hour (1 hour for telomerase reaction, 10 minutes for PCR, and 20 
minutes for CPT). In the future, patients may be informed their cancer diagnosis on the 
same day utilizing a LoC chip performing the present assay. 
4.3.8. Evaluation of Telomerase Inhibitory Effects of Anionic Phthalocyanine 
Telomeric DNA can form four-stranded DNA called G-quadruplex [42, 43]. 
G-quadruplex does not serve as a substrate DNA for telomerase [44]; therefore, 
G-quadruplex-ligands that inhibit telomerase activity are promising as anticancer drugs 
[45]. For development of G-quadruplex-ligands, a quantitative evaluation of the 
telomerase inhibitory effects of such ligands is required. Reportedly, the common 
one-step TRAP assay is not appropriate for such evaluation because 
G-quadruplex-ligands can also inhibit PCR and lead to false negative results [46]. In 
contrast, the A-PCR/CPT assay can accurately evaluate the inhibitory effects of these 
ligands because this assay should eliminate PCR inhibition as demonstrated above. To 
assess this supposition, the A-PCR/CPT assay was used to evaluate the effects of a 
G-quadruplex-ligand on telomerase activity. For this purpose, the A-PCR/CPT assay 
was carried out with lysate from 1000 HeLa cells and in the presence of 0-20 µM 
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Fig. 4-8. Fluorescence intensity results from the A-PCR/CPT assay in the presence of various 
concentration of Cu-APC. Each data point is the average calculated from the three replicate data 
sets and each error bar represents the standard deviation.  
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Cu-APC, which binds to G-quadruplex DNA specifically over dsDNA and inhibits 
telomerase activity [47-50]. The normalized fluorescence intensity at 520 nm was 
plotted versus the concentration of Cu-APC, and the fluorescence decreased as a 
function of the concentration of Cu-APC (Fig. 4-8). This result indicates that Cu-APC 
inhibited telomerase. Based on the plot, the IC50 value of Cu-APC for telomerase 
activity was estimated to be 2.2 ± 0.5 µM. The value is identical to the IC50 value (1.2 
or 1.4 µM) obtained by an improved TRAP assay [47, 50], which reduced the influence 
of Cu-APC on PCR by diluting the telomerase reaction products with Cu-APC. 
Therefore, the A-PCR/CPT assay can be used to screen for G-quadruplex-ligands that 
inhibit telomerase activity. 
4.4. Conclusions 
A telomerase assay based on A-PCR [29, 30] on MBs and subsequent application of 
CPT [31] involving a probe RNA and RNase H was developed. CPT with probe RNA 2 
(5’-CCCUAACCC-3’) detected MSTP comprising 5’-(GGGTTA)16-3’ with detection 
limit of 0.1 fmol; therefore, CPT was two orders of magnitude more sensitive than 
conventional gel electrophoresis analysis. Furthermore, this telomerase assay with probe 
RNA 2 could be used to specifically and sensitively detect HeLa cells among cell 
populations comprising predominantly NHDF cells. The detection limit of this assay for 
HeLa cells was 50 cells; therefore, this assay was more sensitive than the common 
TRAP assay. Moreover, it was shown that the assay eliminated false negative results 
caused by common components of clinical samples that inhibit PCR such as bile salt, 
hemoglobin, and heparin. These results demonstrated that the assay developed here is 
practical for detecting cancer cells in clinical samples. 
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5. Perspective 
5.1. Elucidation of Rules to Design Anticancer Drugs with Efficient Telomerase 
Inhibitory Effect 
Most G-quadruplex-ligands developed to date are cationic for telomerase inhibition 
by strong binding to G-quadruplex via electrostatic attractive interaction [1-3]. However, 
this thesis elucidated that anionic functional groups of G-quadruplex-ligands contribute 
to G-quadruplex-binding and telomerase-inhibiting capacites of the ligands under 
abundant dsDNA condition and MC conditions. In addition, large pi-planar compounds 
such as phthalocyanine and porphyrin preferentially accumulated in cancer cells [4], and 
anionic compounds are expected to exhibit long blood retention properties and high 
transfection efficiency because they do not participate in electrostatic interactions with 
lipoproteins or seric proteins [5, 6]. Consequently, it was demonstrated that large 
pi-planar compounds with anionic functional groups can be new scaffolds to develop 
G-quadruplex-ligands as anticancer drugs. This strategy may also be useful to improve 
the capacity of numerous G-quadruplex-ligands reported previously. 
Furthermore, recent bioinformatic studies have shown that many putative 
G-quadruplex-forming sequences in the genome are enriched in the promoter regions of 
oncogenes including c-MYC, c-kit, HRAS and KRAS [1, 2, 7-10]. These bioinformatic 
studies strongly indicate that G-quadruplexes can influence carcinogenesis by 
modulating transcription of oncogenes. Importantly, some G-quadruplex-ligands 
regulate the expression of these oncogenes by binding to G-quadruplexes in the 
promoter regions [1, 2, 7, 8]. Thus, anionic G-quadruplex-ligands are also expected to 
bind to G-quadruplexes in the promoter regions of oncogenes and regulate their 
expression. 
5.2. Development of an Assay for Telomerase Activity without False Negative Results 
The conventional telomerase activity assay, TRAP assay, is not applicable for 
practical cancer diagnostics, because it is susceptible to polymerase inhibition by 
clinical extract, which leads to the false negative results [11]. To solve the problem, the 
novel telomerase assay utilizing A-PCR on MBs and CPT technology was developed in 
this thesis. Because of high-sensitive detection of cancer cells and avoidance of false 
negative results that preclude a clinical application of the conventional TRAP assay, the 
present assay should make a contribution to an accurate cancer diagnosis. For a clinical 
application of the present assay, it is preferable that all the procedures are automated 
using LoC technology. Various LoC devices utilizing MBs have already been developed, 
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because attachment of MBs to the target molecules including DNA, RNA, and proteins 
allows for the manipulation [12]. Also, the author’s group succeeded to develop a 
silicon based PCR chip, which allows a rapid PCR amplification (30 cycles for 15 
minutes) using only 2 µL of PCR solution [13, 14]. Therefore, the LoC device 
performing the present assay can be realized in the future. 
Among various cancer diagnoses, a cervical cancer diagnosis may most need the LoC 
device with the present assay. Although cervical cancer is usually diagnosed by cervical 
cytology, the diagnosis is not accurate and depends on a proficiency of a 
cytotechnologist. Recently, DNA testing of human papillomavirus (HPV), of which 
infection is the first step for the cervical cancer development, was approved for the 
accurate diagnosis by Food and Drug Administration (FDA). However, HPV DNA 
testing should also be unuseful, because most HPV infections are temporary and 90% of 
infections are gone in 2 years without causing cervical cancer. Thus, it is critically 
important to detect only HPV with a high risk for cervical cancer. Previous studies on a 
cervical cancer development showed that E6 and E7 proteins of HPV with such a high 
risk activate hTERT expression by interacting with transcriptional repressors including 
USF1 and USF2 [15], and activators including c-Myc/Mac heterodimer [16, 17]. 
Therefore, the LoC device with the present assay should be of great help in the accurate 
diagnosis of cervical cancer. 
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